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SUMMARY 
Almost all current tests for biomarkers require venous blood draws, extensive sample 
processing, and analysis with complex equipment. Inexpensive, easy-to-use tests are 
critical for expanding healthcare to under-developed regions, but the requirement for 
reliable quantification in complex sample types (like blood) has been a critical roadblock 
in developing such diagnostics. Microbial-based biosensors have the potential to serve as 
a robust and generalizable platform for such diagnostics, as microbes can sense a wide 
variety of clinically relevant analytes and can produce colored outputs that are visible to 
the naked eye. Further, cell-free systems, which use bacterial protein extract to implement 
genetic networks, can be freeze-dried and rehydrated in the sample to be analyzed, enabling 
long-term storage at ambient temperatures and point-of-care test implementation and 
interpretation. This work describes the development of bacteria-based diagnostic assays 
that use bacterial sensing methods to control production of different colored readouts that 
are visible to the naked eye, yet quantitative and robust to the interference effects seen in 
complex samples. Using this platform, I develop a nearly field-deployable test for zinc 
deficiency (which is estimated to cause over 100,000 childhood deaths annually) that 
accurately measures clinically relevant zinc concentrations. The test requires just a finger-
prick of blood, is robust to temperature variation, and can be freeze-dried for long term 
storage. I also use this approach to measure other classes of biomarkers, demonstrating a 





Biosensors have been developed for a wide variety of compounds, but the vast majority of 
sensors use fluorescence as a readout (necessitating equipment to interpret), respond to a 
limited concentration range (often preventing testing of relevant concentrations) and do not 
work in complex matrices (preventing testing of biological samples). Bacterial biosensors 
that overcome these problems could be particularly useful in developing low-cost, point-
of-care diagnostic tools that could expand healthcare to low-resource settings and better 
enable large-scale public health assessments. Bacteria can be engineered to produce 
colored pigments, potentiating the creation of sensor cells that produce easy-to-interpret, 
visible outputs. Related bacterial “cell-free” assays have been recently used in diagnostic 
development for infectious diseases, but their scope has been limited to detection (not 
quantification) of diseases with nucleic acid biomarkers.  
1.1  Bacterial biosensors for point-of-care diagnostics 
  Low-cost, point-of-care diagnostic tools have the potential to transform healthcare 
by eliminating the cost and logistical challenges associated with sample transport, 
advanced analytical equipment, and trained personnel. Further, point-of-care tests enable 
diagnoses in low-resource settings, which can help expand healthcare to locations that do 
not have the infrastructure and resources to support analytical laboratories. The World 
Health Organization has set the ASSURED criteria to describe the ideal test for use in low-
resource settings: a test should be Affordable, Sensitive, Specific, User-friendly, Rapid and 
Robust, Equipment-free, and Deliverable to the end user.  
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Bacteria-based biosensors have the potential to expand the scope of point-of-care 
tests to a wide variety of diseases and conditions. All bacterial biosensors have two main 
components: a sensing method that responds to the target compound, and a signal 
transduction method that leads to a detectable output. Bacteria have a wide variety of 
naturally evolved sensors that can be harnessed to control cell output. Allosterically-
regulated transcription factors differentially control gene expression upon metabolite 
binding1; two-component systems transduce external signals into transcriptional changes2; 
and small-molecule responsive riboswitches can alter transcriptional termination and 
protein translation3. Engineering strategies such as directed evolution can be used to alter 
substrate specificity or to engineer entirely new sensing domains4, further broadening the 
scope of compounds that can be detected with biosensors. In most existing biosensors, 
signal transduction leads to altered expression of a reporter gene, such as a fluorescent 
protein or an enzyme that can cleave a substrate into a colored product. Bacteria can be 
engineered to produce distinct colored proteins proteins or pigments that are visible to the 
naked eye, potentiating the possibility of equipment-free detection. The resulting 
equipment-free tests would be particularly useful in low-resource settings, as they would 
reduce the cost and logistical challenges associated with sample transport, storage, and test 
interpretation. 
Whole cell-biosensors have already been developed to detect and respond to a 
variety of compounds. Engineered cells can detect and respond to levels of pollutants5,6, 
pathogenic bacteria7, and inflammation markers8,9. Bacterial “theranostics” take biosening 
a step further and can deliver a drug, therapeutic protein, or other payload upon sensing a 
 3 
target biomarker. Responsive bacterial therapies show promise for treatment of cancer10,11, 
metabolic disorders12,13, and gut inflammation14.  
 Cell-free sensor systems have recently emerged as an alternative bacteria-based 
biosensing approach, and these systems show great potential for use in point-of-care 
diagnostic tools. Cell-free systems (discussed in more depth below) use bacterial proteins 
to implement genetic programs. They have been successfully used to make a suite of 
infectious disease diagnostic tools that can specifically and sensitively detect essentially a 
user-defined nucleic acid sequence15,16. These systems can be lyophilized and stably stored 
on filter paper, function properly upon rehydration, and produce visible, enzyme-mediated 
output within 30 minutes of sample addition.  
1.2 Prevalence and assessment of micronutrient deficiencies 
In efforts to expand the scope of bacteria-based biosensors for diagnostic 
applications, this thesis focuses primarily on developing tools to diagnose micronutrient 
deficiencies, with the lack of available micronutrient diagnostic tools being significant 
motivation. Further, micronutrient deficiencies are the underlying cause for many diseases, 
which makes their treatment a high global health priority.  
 Micronutrients are vitamins and minerals essential for proper growth and 
development, and micronutrient deficiencies account for over 3 million annual childhood 
deaths and 35% of the childhood disease burden17. Micronutrient deficiencies are generally 
treated at a population level through supplementation or food fortification programs, but 
survey data on specific affected areas are required to inform intervention programs. 
Micronutrient deficiencies, often described as “hidden hunger”, have no immediately 
 4 
apparent physical markers and require quantitative biomarker assessment for accurate 
diagnoses. This is in contrast to macronutrient deficiencies, which can be easily diagnosed 
through anthropometric measurements. 
 The Demographic Health Surveys (DHS) program performs regular assessments of 
public health, and the program can incorporate micronutrient tests into these surveys if 
“field-friendly” micronutrient analysis methods are available. To be considered field-
friendly, tests must be done in the field, require minimal equipment and minimal training 
to perform, have an easy sample collection and transport protocol, and have a short 
turnaround time18, requirements that are largely in agreement with the WHO’s ASSURED 
guidelines. Through conversations with DHS leaders, I have learned that a useful test must 
produce results within four hours, which is the time it usually takes to complete a household 
survey that assesses multiple factors (ie: water quality, access to education, child height 
and weight). This would allow a surveyor to perform the test at the beginning of the survey 
and have results before leaving the home. Currently, DHS surveys are limited to assessing 
anemia (measured via hemoglobin quantification) largely because of the field-friendliness 
of the hand-held Hemocue device, which can quickly report hemoglobin levels from a 
fingerprick of blood. To date, there is no fully field-friendly test for any other nutritional 
biomarker.  
 Efforts to create new micronutrient diagnostic tools have largely focused on 
developing assays that can be performed in minimally equipped regional laboratories. 
These assays could be used in a small subset of public health surveys that have additional 
resources and the capacity for short-term sample storage and transport. A recently 
developed multiplexed ELISA platform19 enables quantification of several micronutrient 
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biomarkers, including those for iron, vitamin A, and iodine, and it is being expanded to 
quantify markers for folate and vitamin B12
20. However, there is currently no assay for zinc, 
which is one of the six primary micronutrients of global health interest21. Zinc deficiency 
alone is estimated to affect 17% of the world’s population22 and is responsible for over 
100,000 annual childhood deaths17. Zinc deficiency is most prevalent in the developing 
world (Figure 1) and has the most negative effects on women and small children23.  
 
Figure 1: Estimated country-specific prevalence of inadequate zinc intake. 
Reproduced from Wessells and Brown, Plos One 201222.  
 The most reliable biomarker for zinc deficiency is plasma or serum zinc 
concentration. However, plasma zinc still has several disadvantages as a biomarker: it can 
vary based on food intake, time of day, and a variety of other factors that are decoupled 
from actual zinc deficiency. This variation makes plasma zinc an unreliable marker of 
individual zinc status, but an adequate marker of population zinc levels21. The threshold 
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for healthy plasma zinc is between 57 and 74 g/dL21, or between 8.7 and 11.3 M, with 
physiological zinc concentrations ranging between 2 and 30 M24.  
 Currently, assessment of serum zinc levels requires sample shipment, extensive 
sample processing, and analysis with advanced analytical equipment. To avoid red blood 
cell lysis and artificial increase of plasma zinc levels from the resulting influx of zinc, 
samples must be shipped under constant refrigeration, a process referred to as “cold chain” 
shipment. For analysis, serum samples must be acid-digested at high pressure and then 
measured with atomic absorption spectrometers (AAS) or inductively coupled plasma mass 
spectrometers (ICP-MS). Isolated academic studies have had the resources to support this 
analysis process, but the costs and logistical challenges of maintaining cold chain and the 
costs of current testing methods have prevented population-level assessment of zinc status 
at the scale needed to effectively treat zinc deficiency.  
1.3 Previous work towards a whole-cell zinc biosensor 
 A bacteria-based biosensor could fill the need for a field-friendly zinc test, and 
could be potentially expanded to assess other micronutrients. As obligate consumers of 
micronutrients, bacteria have the cellular machinery to sense and respond to varied 
micronutrient concentrations in their extracellular environments. Our group has already 
created a preliminary E. coli zinc sensor by harnessing zinc-responsive transcription factors 
to control production of pigmented metabolites25,26. However, these initial sensor cells are 
far from being field-deployable. These sensor cells always produce some pigment, which 
necessitates that the cells be grown from a very small inoculum so that coloration due to 
initial cell mass is minimal. This requirement leads to overnight assay times, which are far 
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longer than the four-hour threshold set for use in a DHS survey. Further, these sensor cells 
respond to zinc concentrations outside of the physiologically relevant range. To make the 
device more field-friendly, it is vital to reduce the time to coloration and tune the response 
range.  
1.4  Metabolic pigments for visual test interpretation 
In our group’s continued effort to develop a biosensor for zinc deficiency, we have 
used pigmented metabolites as the sensor’s output because of their advantages in enabling 
equipment-free test interpretation. Commonly used reporters all require equipment to 
interpret: fluorescent proteins are often not visible to the naked eye, necessitating use of a 
fluorimeter; and while commonly used enzymatic reporters (such as β-galactosidase) 
cleave substrates into visibly colored products, test interpretation requires measuring 
intensity of color production, which cannot be easily done by eye and thus necessitates use 
of a spectrophotometer. By using multiple pigment reporters, we can engineer discrete 
color changes, which can enable the user to interpret test output as easily as reading a litmus 
test and can minimize the subjectivity inherent to quantifying color intensity. We have 
previously used the pigments violacein, lycopene, and -carotene as reporters to indicate 
relative low, medium, and high levels of extracellular zinc25,26. 
 Violacein is a pigment produced by the bacterium Chromobacterium violaceum, 
and metabolic engineering of violacein has been extensively investigated27-33 because of 
its medical potential: it has been demonstrated to have antibiotic, antiviral, and antitumor 
activity28. Additionally, the complexity and pigmented intermediates of the violacein 
biosynthesis pathway (Figure 2A) make it a useful testbed for the development and 
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validation of novel metabolic engineering strategies29,31,34. Lycopene and -carotene are 
pigments in the carotenoid pathway (Figure 2B) and have also been targets of metabolic 
engineering efforts35-40. Two different pathways produce the precursors needed for 
carotenoid synthesis: the non-mevalonate pathway, which naturally occurs in bacteria, and 
the mevalonate pathway, which can be heterologously expressed in bacteria. Both 
pathways have been used to overproduce the metabolic precursors both for carotenoids and 
for other medical and commercial products41-43.   
 
Figure 2: Pigment production pathways, with different pigmented metabolites 
indicated by colored boxes.  
(A) Violacein synthesis pathway. Five enzymes convert tryptophan to the purple 
pigment violacein, and different enzyme combinations can produce different colored 
pigments. (B) Carotenoid synthesis pathway. Both the nonmevalonate and 
mevalonate pathways produce FPP, which is the immediate precursor to the 
carotenoid pathway. Three enzymes are required to convert FPP into lycopene, and 
a single enzyme converts lycopene into β-carotene.  
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 Engineering cells to produce metabolites (such as pigments) requires more complex 
cell engineering than what is required for protein overproduction. Metabolites are produced 
through multi-enzymatic pathways that draw precursors from naturally-occurring cell 
metabolism. Overexpressing these pathways can deplete vital metabolites from the cell, 
cause cofactor imbalances, and lead to accumulation of toxic pathway intermediates, all of 
which lead to low cell viability and construct stability44. Optimization of enzyme 
expression levels can help to balance flux and prevent buildup of intermediates, but as the 
number of enzymes in a pathway increases, the potential design space dramatically 
increases, and combinatorial assessment becomes intractable without high-throughput 
assembly and screening processes. Metabolite-responsive control methods offer a more 
rational approach to balancing metabolic flux. Metabolite-responsive promoters can 
control production of downstream enzymes so that the cell produces more enzymes as 
substrates accumulate45,46. However, since this approach requires the presence of a 
regulator that responds to the target metabolite, it is limited to pathways that have 
transcription factors that respond to pathway intermediates. 
 Engineering cells to not just produce pigments but to selectively produce certain 
pigments in response to specific inputs poses even further engineering challenges. Sensor 
cells must be able to produce visible pigment in a reasonable time period, but more 
importantly, they must maximize selectivity of pigment production so that only the desired 
pigment is produced47. For such an application, cells must be able to flexibly respond to 
different signals and then tightly control cell output to fully repress metabolic flux through 
competing pigment pathways. Previous metabolic engineering work has demonstrated the 
difficulty of fully repressing pigment production: when the lycopene production pathway 
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was controlled by an inducible promoter, lycopene yields were higher when cells were 
grown without the inducer, meaning that enough baseline protein was produced to catalyze 
lycopene production in the uninduced state40. 
 Dynamic metabolic control strategies have been successfully used to separate cell 
growth and metabolite production phases48,49, but these have primarily focused on 
maximizing final overall yields (rather than response selectivity). Metabolite valves 
redirect metabolic flux from central carbon metabolic pathways to competing production 
pathways50,51, and effectively shift the bulk of metabolic flux upon recognition of a target 
molecule. However, these still permit some baseline expression through competing 
pathways, which can actually be beneficial for overall performance. For situations where 
complete control of metabolic flux is required (such as a pigment-based biosensor), this 
minimal leakage can lead to visible levels of pigment production that can completely 
confound sensor interpretation.  
 In previous work developing a responsive sensor, our group has demonstrated the 
difficulty of using pigmented metabolites as outputs and has also begun to develop 
engineering tools to harness metabolism for sensor output. We used a zinc-responsive 
promoter to control production of CrtY, a single enzyme that converts lycopene to -
carotene, and found that uninduced, baseline expression of CrtY converted all lycopene to 
-carotene, preventing a lycopene-only state. A combination of translational and post-
translational control was necessary to compensate for leaky expression and enable 
discretely red and orange sensor cells25. Creation of a field-deployable zinc sensor requires 
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even more complex regulatory systems, and will likely require layered regulation to 
precisely control pigment production. 
1.5 Cell-free expression systems for diagnostic applications 
 While whole biosensors have the potential to meet many of the ASSURED 
requirements for point-of-care tests, a cell-free device has the potential to be even more 
field-friendly. Cell-free expression (CFE) systems use bacterial proteins, rather than whole 
cells, for protein production. Removing the cell membrane creates an open system, giving 
the user more control over substrate addition and reaction conditions. It additionally 
removes the requirement for cell survival and growth, enabling better allocation of 
resources to target protein production.  
 Cell-free systems have been increasingly used in biotechnology for high-yield 
protein production, circuit characterization, and metabolic pathway prototyping. Cell-free 
systems can be classified into two general categories: those made with purified protein 
components52-54 and those made with crude cell lysate55,56. Both types of systems are 
commercially available from scientific vendors, but limitations in yield, volume, reaction 
rate, and cost per reaction have motivated exploration of different extract preparation 
methods.  
 Cell-free expression systems that use crude cell lysate have been created with 
protein extract from a wide variety of cell types, including bacterial cells, rabbit 
reticulocytes, insect cells, and wheat germ cells57. For expression of most proteins, 
bacterial-based cell-free systems are the preferred choice, as they have the highest protein 
yields, the shortest preparation time, and the lowest production costs. While E. coli is the 
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most commonly used bacterial strain for lysate production, other bacterial species have 
recently been used for extract preparation in efforts to decrease extract production time, 
increase protein yield, and increase extract robustness and versatility58-60. Eukaryotic cell 
extracts are useful for producing proteins that are insoluble in bacterial systems or proteins 
that require post translational protein modifications such as glycosylation. Of the 
eukaryotic expression systems, wheat germ extract has been the most widely studied and 
has the highest protein yield, but the extract preparation method is quite time consuming, 
and protein yields are still lower than what can be achieved using bacterial extracts57.  
 All bacterial extract preparation methods follow the same general process, with 
modifications based on the target application. Bacterial strains optimized for protein 
expression are grown in rich media and isolated in exponential phase. Cells are then lysed, 
and lysate is centrifuged to remove the cell wall and genomic DNA. Effective cell lysis is 
critical to obtaining high lysate function and protein yields. Homogenizers have 
traditionally been used in extract preparation61, but high equipment cost and variability has 
motivated exploration of alternative systems, such as bead beating62 and sonication63. For 
all methods, it is critical to achieve an energy-input optimum to fully lyse cells without 
deactivating enzymes. Subsequent lysate incubation and dialysis can increase expression 
from native bacterial promoters64. 
 Once the cell lysate is prepared, protocols for running cell-free reactions are similar. 
The most widely used expression protocols require addition of components that mimic the 
physiological conditions of the bacterial cytoplasm, through addition of salts, energy 
sources, and crowding reagents65. The final reactions consist of protein extract, the plasmid 
encoding the target proteins or regulatory elements, nucleotide triphosphates, amino acids, 
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tRNA, crowding reagents, cofactors, and a high-energy phosphate source, such as 
phosphoenolpyruvate (PEP) or 3-phosphoglycerate (PGA).  
 Beyond fast protein production, a primary advantage of bacterial cell-free systems 
is their utility in rapid prototyping. Implementing circuits in whole-cell systems generally 
requires cloning all genes and regulatory elements onto the same plasmid and then varying 
promoter and RBS strengths are varied to tune relative expression. Combinatorial 
exploration of expression levels thus requires cloning dozens or even hundreds of 
constructs. In cell-free reactions, relative protein expression levels can be easily modulated 
through gene dosage (adding different relative amounts of each plasmid), which eliminates 
the need for extensive cloning and thus facilitates rapid testing of complex circuits66-68. To 
make this process even faster, linear DNA can be used instead of plasmids69, which further 
reduces the design-build-test cycle from multiple days (for standard cloning procedures) to 
under eight hours70. Similar approaches can be used to prototype metabolic pathways in a 
high-throughput fashion, which can then inform bacterial strain design for metabolic 
engineering applications71,72. 
 Cell-free systems have already been used to create diagnostic tools with global 
heath applications: RNA-based cell-free sensors rapidly detect Ebola and Zika viruses15,16, 
and related CRISPR-based diagnostics detect pathogens with attomolar sensitivity73-75. 
Allosterically regulated transcription factors15,76,77 and riboswitches78 can also control 
output in cell-free systems, potentiating the expansion of cell-free diagnostics to diseases 
and conditions that require assessment of diverse types of biomarkers.  
1.6 Contribution of this thesis 
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 In this dissertation, I develop methods to quantify biomarker levels in an 
equipment-free fashion using bacterial-based biosensors. I create tunable whole-cell and 
cell-free sensors that produce different colored outputs based on biomarker concentration. 
Tests semi-quantitatively measure biomarkers in real human serum, and test interpretation 
is as easy as reading a litmus test. I create a complete system for diagnosis of zinc 






 ENGINEERING PIGMENTS FOR USE AS 
REPORTER OUTPUTS 
Portions of this chapter are reproduced from my publication “Precise control of lycopene 
production to enable a fast-responding, minimal-equipment biosensor”79 in Metabolic 
Engineering. 
2.1 Introduction 
The use of pigments as biosensor readouts holds great promise for emerging 
biosensor applications. When substituted for widely-used fluorescent reporters, pigment 
readouts can be interpreted without advanced equipment because they are visible to the 
naked eye, making them useable even in resource-poor settings. While there have been 
isolated examples of the use of colors as biosensor readouts15,16, this approach is yet to be 
widely adopted. 
 One would expect the use of pigmented reporters to be a straightforward task given 
the breadth and depth of knowledge about pigment biosynthesis. Pigmented molecules are 
a common metabolic engineering target, whether due to their intrinsic value, their value as 
precursors, or just as a testbed for metabolic engineering techniques that enable simple 
screening29,30,33,34,80. However, using metabolites as reporters requires more precise control 
than what is necessary for most metabolic engineering applications, since small amounts 
of enzyme can produce visible amounts of pigment and overproduction of certain 
metabolites can be toxic to the cell.  
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 In our group’s previous work towards a whole cell-biosensor for zinc assessment, 
we engineered cells that produce one of three pigmented metabolites—violacein (purple), 
lycopene (red), or -carotene (orange)—based on extracellular zinc concentrations25,26. In 
our initial zinc sensor prototype, the sensor cells always produced some pigment, a design 
selected for simplicity and to minimize ambiguity in readouts. However, this approach 
necessitates that the cells be grown from a very small inoculum so that coloration due to 
initial cell mass is minimal – thus requiring overnight assay times. To make the device 
more field-friendly, an important goal is to reduce the assay’s time to coloration, which we 
are attempting to do by engineering cells that completely repress pigmentation during 
growth and quickly produce the appropriate pigment upon induction. This will enable 
sample addition to concentrated pre-cultured cells, making time to coloration only 
dependent on pigment production rates rather than coupled to the time required to grow a 
sufficiently large mass of cells. 
 In our previous work, we focused on the widely-studied and widely-engineered 
carotenoid pathway, which produces the red pigment lycopene. Overproduction strategies 
— including gene knockouts36,39,81, precursor supplementation40-42,82-84, and dynamic 
regulation of pathway genes38,85 — have greatly improved lycopene yields and titers in 
previous metabolic engineering efforts. However, to use lycopene as a reporter in a 
biosensor, the primary goal must shift from maximizing yields and titers to maximizing 
response specificity. 
 To be effectively used as reporters, pigment production must be able to be turned 
completely off and on based on the state of the system. Here, we aimed to completely 
repress pigment production before inducing the biosynthetic pathway for downstream 
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biosensor readout. Previous metabolic engineering work has demonstrated the difficulty of 
fully repressing lycopene production – a goal that is critical for biosensing applications. 
When the enzymes that produce lycopene were expressed from an IPTG-inducible 
promoter, high lycopene yields and titers were achieved without any IPTG induction, 
meaning that enough protein was produced even in the uninduced state to catalyze lycopene 
production40. In fact, IPTG induction actually reduced both cell growth and lycopene 
production, proposed to be due to toxicity effects. Since maximum pigment production 
does not correspond with maximum protein production, precise control of the induced 
expression level is thus necessary to completely control pigment production.  
 To deal with the known difficulties in controlling lycopene production, we sought 
to investigate the abilities of different transcriptional and translational control mechanisms 
to enable both complete repression of lycopene when uninduced as well as fast production 
of visible amounts of lycopene upon induction. We chose to explore three commonly used 
promoter systems — the Lac, Ara, and T7 systems — that are all considered very inducible 
(at least in terms of dynamic range) but have varying levels of uninduced leaky expression, 
though Ara is widely considered to be tightly repressible and not leaky86,87. We sought to 
characterize the levels of unwanted protein expression in these promoter systems and 
reduce this unwanted expression by manipulating cis regulatory elements. Once systems 
were developed that could fully repress lycopene, we compared the time to response of the 
three different promoter systems. Finally, we explored the effect of metabolic precursor 
supplementation on the time to visible lycopene production upon induction.  
 This chapter presents approaches that ultimately enabled full repression of lycopene 
in the absence of an inducer while also enabling production of visible amounts of lycopene 
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within two hours of induction, a reduction of over an order of magnitude compared to the 
previously reported strategy. Promoter engineering, RBS strength modification, and 
pathway engineering were all explored, and the effectiveness of each approach is 
evaluated.  
2.2 Materials and Methods 
2.2.1 Materials 
 T4 DNA ligase, T5 exonuclease, Taq ligase, Phusion polymerase, Q5 polymerase, 
and restriction endonucleases were purchased from New England Biolabs (Ipswich, MA, 
USA). E.N.Z.A. Plasmid Mini Kits were purchased from Omega Bio-tek (Norcross, GA, 
USA), and QIAquick PCR Purification Kits and QIAquick Gel Extraction Kits were 
purchased from QIAGEN (Valencia, CA, USA). A lycopene standard was purchased from 
Millipore Sigma (St. Louis, MO). Sudan I (95%) was purchased from TCI America 
(Portland, OR, USA).  
2.2.2 Strains and plasmids  
 Escherichia coli K-12 DH10B (New England Biolabs, Ipswich, MA) was used for 
plasmid assembly and for all protein and metabolite production. The plasmid pSB3T5, with 
a p15A origin, was taken from the Standard Registry of Biological Parts. To better enable 
colony selection based on antibiotic resistance during construct assembly, we made 
variations of the pSB3T5 plasmid by replacing the tetracycline resistance gene with either 
a kanamycin or chloramphenicol resistance gene. Consistent protein expression across 
plasmids was verified with fluorescence (data not shown), and these plasmids were used 
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for all heterologous protein production. The plasmid pSB6A1, which is a derivative of the 
pBR322 plasmid, was obtained from the Standard Registry of Biological Parts and used 
for expression of the mevalonate genes. 
2.2.3 Cloning and construct assembly 
All constructs were assembled with either Gibson assembly88 or restriction 
endonuclease digestion of components and subsequent ligation and transformation 
following the BioBricks idempotent standard assembly89. For fluorescent characterization, 
mRFP was obtained from the Registry of Standard Biological Parts (bba_E1010), and the 
barcode downstream of the coding sequence was removed. The genes crtE, crtB, and crtI 
were amplified from Part bba_k274100 of the Registry of Standard Biological Parts and 
were originally isolated from Pantoea ananatis.  
Mevalonate pathway experiments used genes from the plasmid pJBEI-640983, 
which was obtained from Addgene (Cambridge, MA, USA). Mevalonate pathway genes 
were amplified from this plasmid, a ribosomal binding site with a putative translation rate 
of 500 as determined by the RBS calculator90 was added to each gene, and genes were 
placed under control of the arabinose-inducible promoter pBad and cloned into the plasmid 
pSB6A1.  
2.2.4 Promoter Assembly  
 The promoters PBad (bba_I0500) PLac (bba_R0011) were obtained from the Registry 
of Standard Biological Parts and used as templates for promoter modifications. PLac is a Pλ 
-based promoter with two operator sites for LacI repression. PLac,weak was purchased as a 
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gene fragment from IDT (Coralville, IA). PLac,weak,2 was assembled by adding an additional 
lac operator site to PLac,weak through Gibson assembly. All T7 promoters were assembled 
with Gibson assembly. The T7 RNA polymerase was taken from the Registry of Standard 
Biological Parts (bba_K145001) and placed under control of PLac,weak. In all Lac-controlled 
constructs, LacI was constitutively expressed from the promoter Pλr (bba_R0051).  
2.2.5 Cell culture 
 For RFP expression, freshly transformed DH10B colonies were inoculated in 
triplicate into 5 mL LB medium and grown at 37C and 180 rpm for 18 hours. 1 L of each 
culture was then added to 150 L of medium containing the appropriate concentration of 
inducer (either IPTG or arabinose) in a 96-well plate, and the plate was incubated at 37C 
and 180 rpm for 18 hours and then analyzed. For time course fluorescence experiments, 15 
L of overnight cultures was added to 135 L of fresh media, and plates were incubated in 
a Biotek Synergy H4 plate reader at 37C with medium-strength shaking and analyzed 
every 20 minutes.  
 For lycopene expression, freshly transformed DH10B colonies were inoculated in 
triplicate into 5 mL LB medium containing the appropriate inducer and grown at 37C and 
180 rpm for 18 hours. For time-course experiments, overnight cultures were diluted to an 
OD of 0.15 in 50 mL of fresh medium, the appropriate inducer was added, and the sample 
was aliquoted into culture tubes corresponding to different time points. OD and lycopene 
content were measured at the time of inoculation, every hour for six hours, and at 18 hours.  
 LB medium composed of 10 g/L NaCl, 5 g/L yeast extract, and 10 g/L tryptone was 
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used in all experiments. Either IPTG or arabinose was used for induction, and the following 
antibiotics were used for appropriate selection: tetracycline (15 g/mL), chloramphenicol 
(33 g/mL), kanamycin (30 g/mL), and carbenicillin (100 g/mL).  
2.2.6 Measurement of optical density and fluorescence  
 Optical density of samples was quantified by measuring the absorbance at 600 nm 
either in a ThermoFisher Genesys 20 spectrophotometer with a 10 mm path length or in a 
Biotek Synergy H4 plate reader. 1 mL of culture was used for spectrophotometer 
measurements, and 150 L of culture in a 96 well plate was used for plate reader 
measurements. Calibration curves were made for each instrument and used for uniform 
reporting of optical density. All optical densities reported correspond with those taken in 
the spectrophotometer. For RFP quantification, fluorescence at 585 nm excitation and 610 
nm emission was measured on a Biotek Synergy H4 plate reader. All reported fluorescence 
values are background-subtracted and normalized to optical density.  
2.2.7 Lycopene extraction and HPLC analysis 
Either 250 L, 500 L, or 1 mL of bacterial culture was pelleted at 18,000 rcf for 
5 minutes. Cell pellets were resuspended in 50 L of ultrapure water. Lycopene was 
extracted with 1 mL of acetone at 50C for 20 minutes. A heat block was used to maintain 
temperature, and extractions were vortexed every 5 minutes. Cellular debris was pelleted 
at 18,000 rcf for 5 minutes, and 500 L of supernatant was removed for analysis. Sudan I 
was used as an internal standard91 and added to the acetone used for extractions at a 
concentration of 1 g/mL.  
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 All HPLC analysis was conducted on a Shimadzu Prominence UFLC using an 
Agilent C18 4.6 mm x 50 mm column with a 5 μm particle size and a Shimadzu photodiode 
array detector. A solvent ratio of 50:30:20 acetonitrile:methanol:isopropanol was used as 
the mobile phase92 and run at a flow rate of 1 mL/min with a 25 μL sample injection 
volume. Absorption was detected at 471 nm. Retention times and peak intensities were 
compared to analytical standards spiked into control extractions from DH10B cells, and 
the internal standard Sudan I was used to account for acetone evaporation during the 
extraction protocol and for instrument drift. 
2.3 Results  
2.3.1 Standard inducible promoter systems cannot repress lycopene production 
 Three inducible promoter systems were tested for their ability to control lycopene 
production: PLac, PBad, and PT7. The promoter PLac is a synthetic Pλ-based promoter with 
two operator sites for LacI repression, and the promoter PBad was originally isolated from 
the E. coli genome. LacI was constitutively expressed from the promoter Pλr, and AraC was 
expressed from its native promoter that promotes transcription in the opposite direction of 
PBad. To confirm the inducibilty of PBad promoters, each was used to control RFP 
production (Figure 3A). The PLac and PBad,weak systems were then used to control the crtEBI 
genes, which code for the enzymes that produce lycopene. Successful clones of the PT7 
system controlling crtEBI could not be isolated, which may have been due to toxicity 
caused by higher baseline levels of crtEBI. 
 In both the PLac and PBad systems, cells had clearly visible lycopene production 
when no inducer was present (Figure 3B). The PBad system had a significant increase in 
 23 
lycopene production at 1x10-4 percent arabinose, but lycopene production decreased with 
further addition of inducer. The PLac system had consistent specific lycopene production at 
all inducer concentrations, though with an insignificant downward trend (Figure 3C). Both 
promoter systems exhibited reduced cell growth with addition of inducer: compared to the 
uninduced state, fully induced cultures had 50% fewer cells with PBad -regulated lycopene 
production and 98% fewer cells with PLac -regulated lycopene production (Figure 3D). 
DH10B cells with negative control PLac and PBad vectors showed only slight decreases 
(about 15%) in terminal OD when fully induced and produced no detectable lycopene. 
 Inability to repress lycopene and cell toxicity upon lycopene induction is consistent 
with previous reports of crtEBI expression from a Lac-inducible promoter40. These 
limitations and constraints pose a significant challenge to using lycopene as a reporter, 
motivating efforts to engineer more repressible promoter systems.  
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Figure 3: Standard inducible promoters cannot adequately control lycopene 
production.  
(A) Inducibility of PLac, PBad, and PT7 promoters. Normalized RFP production from 
the PLac, PBad, and PT7 promoters when induced with varying concentrations of IPTG 
(PLac and PT7) or arabinose (PBad). Error bars represent standard deviation. (B) Cells 
expressing crtEBI from either PLac or PBad that were grown for 18 hours in different 
concentrations of inducer. PLac (top) and PBad (bottom) show visible lycopene 
production in the uninduced state. Terminal cell densities decrease with increasing 
inducer concentration, and cells in all states are visibly red. Numbers correspond to 
M of IPTG for PLac and % arabinose (w/v) for PBad. (C) Lycopene production 
normalized to cellular density. PLac-regulated production is constant at all 
concentrations of IPTG. PBad-regulated production increases only at 0.0001% 
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arabinose. (D) Optical density at 18 hours of cultures with crtEBI expressed from 
either PLac or PBad. Cell density decreases with increasing concentration of inducer. 
All error bars represent standard deviation. 
2.3.2 Promoter engineering decreases leaky protein expression 
 Variants of three common promoter systems—Lac, Ara, and T7—were constructed 
with the goal of decreasing lycopene production in the uninduced state. The PLac and PBad 
promoters used previously were modified to create weaker versions by changing the -10 
and -35 σ70 RNAP binding domains to those of J23113, a very weak promoter. An 
additional PLac variant was constructed by adding a third operator site for LacI downstream 
of the -10 RNAP binding domain. T7 promoter variants were built by adding operator sites 
for LacI downstream from the consensus T7 sequence. In all T7 constructs, T7 RNA 
polymerase was expressed on the same plasmid from the Lac-inducible promoter PLac,weak. 
Table 1 contains the description and sequences for all promoters constructed.  
Table 1: Description and sequences of inducible promoters tested.  
The -10 and -35 RNAP binding domains for PLac and PBad variants and the T7 RNAP 
consensus sequence for the PT7 variants are highlighted in bold. Operator sites for 
LacO are underlined. 
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magnitude in both the Lac and Ara systems. Addition of operator sites for LacI reduced 
uninduced protein expression in the T7 system by orders of magnitude but had no 
significant effect on uninduced protein expression from PLac,weak,2 compared to PLac,weak.  
 Modifications to PBad made the promoter both more repressible and increased its 
dynamic range. PBad is already considered one of the most repressible promoters, and 
PBad,weak is over 30 times more repressible than PBad. Despite this dramatic difference, 
induced expression from pBad was only 3 times higher than from PBad,weak, which is likely 
because AraC recruitment of RNA polymerase largely compensates for the polymerase’s 
decreased affinity for the -10 and -35 RNAP binding domains. PBad,weak has a dynamic 
range of over 5000, which is over ten times greater than any of the other promoters 
characterized.  
 The most repressible promoter from each category was tested for its ability to 
repress lycopene (Figure 4B and Figure 4C), and lycopene repression and induction 
generally did not follow the fluorescent induction trends in Figure 3A. PBad,weak enabled 
repression and induction of lycopene, a marked improvement over PBad’s constitutive 
expression of lycopene. However, when uninduced, cells with crtEBI controlled by 
PBad,weak still had slight, but visible, lycopene production. Cells with crtEBI controlled by 
PLac,weak and PT7LacO2 had obviously visible lycopene in the uninduced state, no change in 
OD normalized lycopene production with induction, and visible reductions in cell growth 
upon induction. Though promoters were engineered to be 10 times more repressible than 
commonly used inducible promoters, only one (PBad,weak) was able to repress lycopene 
production, and even then the repression was incomplete.  
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Figure 4: Discrepancy between fluorescent protein production and lycopene 
production from engineered promoter systems  
(A) Normalized RFP production from the variants of the Lac, Ara, and T7 promoter 
systems described in Table S1. (B) Lycopene concentration normalized to cellular 
density. The most repressible promoter systems were used to control crtEBI, and 
lycopene was quantified. Only PBad,weak shows increased lycopene production with 
induction, likely due to PBad,weak’s very low levels of uninduced protein expression. (C) 
Cells expressing crtEBI from either PLac,weak, PBad,weak, or PT7LacO2. Cells were grown 
for 18 hours with or without inducer. In the uninduced state, PBad,weak is the least 
colored, but still produces visible amounts of lycopene. In all experiments, cells were 
induced with either 1 mM IPTG (for the PLac and PT7 constructs) or with 0.01% (w/v) 
arabinose (for the PBad constructs). All error bars represent standard deviation. 
2.3.3 Qualitative and quantitative evaluation of visible lycopene  
 Since the goal of our work is to have colorless cells that can be induced to be clearly 
colored, we needed to carefully consider our definition of what qualifies as “colorless” and 
“red”. For example, is the uninduced lycopene production of PBad,weak in Figure 4C 
sufficiently low to call it colorless? To minimize potential subjectivity, we set thresholds 
for lycopene visibility based on the OD normalized lycopene concentration of cells 
considered universally “colorless” and universally “red” in a survey that asked 10 different 
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people to match the perceived “redness” of ten different samples to different colors on a 
spectrum (Figure 5). The lycopene levels of samples unanimously considered either 
“colorless” or “red” were then set as the thresholds: samples with OD normalized lycopene 
concentrations < 10.6 (ng/mL)/OD are considered colorless, and samples with OD 
normalized lycopene concentrations > 195 (ng/mL)/OD are considered fully red. These 
thresholds will likely have to be adjusted to fit the final form factor of a biosensor device, 
since the media used (ie: LB vs. M9), culture volume, and cell density all affect the 
apparent “redness” of a sample, even if the lycopene concentration values are the same. 
However, these thresholds are useful for evaluating the effects of different genetic 




Figure 5: Evaluation of “colorlessness” and “redness” in cells producing different 
amounts of lycopene.  
Ten strains expressing different levels of lycopene (A and B) were presented to ten 
different people one at a time in a random order, and each person was asked to match 
the perceived “redness” of each sample to different colors on a spectrum (C). The 
“red” end of the spectrum was set as the color of the cells expressing PLac crtEBI 
(Figure 3A) using the image shown and RGB quantification, and the “white” end of 
the spectrum was set as the color of DH10B cells alone. Three RGB intermediates 
were then linearly interpolated evenly over the “red” and “white” colors. All people 
polled said that samples 9 and 10 matched the furthest red end of the spectrum and 
that samples 1-3 matched the furthest white end of the spectrum. The lycopene values 
of samples 3 and 9 were thus set as the thresholds for colorless and red, respectively: 
Samples with OD normalized lycopene concentrations < 10.6 (ng/mL)/OD are 
considered colorless, and samples with OD normalized lycopene concentrations > 195 
(ng/mL)/OD are considered fully red. 
2.3.4 Reduced RBS strength enables full lycopene repression and proper induction 
 31 
 Since rational promoter engineering was unable to prevent unwanted lycopene 
production, reduction in ribosomal binding site (RBS) strength was explored as another 
way to decrease uninduced protein expression. The crtEBI genes used here have been 
widely used elsewhere; they were originally taken from the Registry of Standard Biological 
Parts (bba_k274100) and already contained RBSs that were added to create a composite 
part. The RBS calculator90 was used to determine the strength of the RBS on each gene, 
and the predicted strengths were comparable (on the same order of magnitude) to the 
predicted strength of bba_B0034 (B34), a commonly used strong RBS from the Registry 
of Standard Biological Parts. Since a strong RBS amplifies the effect of any unwanted 
transcription, reduction in RBS strength was considered a viable option for reduction of 
unwanted protein. As an initial proof of principle, repressible promoter systems were used 
to control RFP production with weaker RBSs, which reduced uninduced fluorescence to 
below the level of detection (Figure 6A), thus supporting RBS strength reduction as a 
viable strategy for reducing unwanted protein and pigment production.  
 RBSs with a range of strengths were then tested for their ability to control lycopene 
production. Operons were assembled with a promoter from each group controlling the 
crtEBI genes with either the medium strength RBS bba_B0032 (B32) or the weak RBS 
bba_B0033 (B33) on all genes. The most repressible promoter from each group was chosen 
to control crtEBI, with the exception of the PLac variants: PLac was used for testing instead 
of PLac,weak or PLac,weak,2 because of their very low dynamic ranges (less than 10). Cells were 
grown with different concentrations of inducer from small inocula, and levels of lycopene 
were determined both quantitatively and qualitatively after 18 hours. With RBSs of B32 
and B33 on the crtEBI genes, cells contained no visible lycopene when uninduced 
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(lycopene < 10.6 (ng/mL)/OD) and produced increased amounts of lycopene with addition 
of inducer. PBad,weak and PT7LacO2 with the RBS B32 had the greatest dynamic ranges, 
maintaining white cells when uninduced and dark red cells (lycopene > 450 (ng/mL/OD) 
at full induction (Figure 6B, Figure 6C).  
 When a strong RBS is on the crtEBI genes, the PLac and PT7LacO2 systems are unable 
to induce lycopene production. These samples also have a lower final cell density, which 
suggests that overproduction of the CrtEBI proteins, lycopene, or an intermediate 
metabolite places some stress on the cell that reduces cell growth and prevents further 
lycopene production. In the PT7LacO2 system with a strong RBS and to a lesser extent in the 
PLac system with the medium-strength RBS, lycopene production increases with partial 
induction (10 M IPTG) but then decreases with further induction. This peak at low levels 
of induction, combined with decreased cell growth at higher induction levels further 
supports that overproduction of lycopene can be toxic to the cell.  
 The induction profiles of RFP and lycopene showed notable differences. Though 
maximum RFP production varied by orders of magnitude across promoter systems (Figure 
6A), maximum lycopene production in all promoter systems was similar (~600 
(ng/mL)/OD). Differences in maximum RFP production could be attributed to variations 
in either promoter strength or effective RBS strength within a promoter system. Because 
of such drastic variation in protein production from each system, as represented by RFP 
levels, it is surprising that maximum lycopene production is so similar across promoter 
systems. The comparable amounts of lycopene produced suggest that either fluorescent 
proteins are not adequate indicators of the amounts of CrtEBI proteins actually produced, 
or that there is an upper limit on the amount of lycopene that cells can accumulate, and 
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increased protein production does not necessarily correspond with increased lycopene 
production.  
 
Figure 6: Effect of RBS strength on lycopene production across different promoter 
systems.  
(A) Lycopene production from each promoter system with three different RBSs on 
the crtEBI genes: original (strong), B32 (medium), and B33 (weak). Weakening the 
RBS decreases uninduced lycopene production. The effect of RBS strength on 
induced lycopene production varies by promoter system. The PLac system has 
maximal lycopene production (in terms of dynamic range) when B33 is on the crtEBI 
genes, and the PBad,weak and PT7LacO2 systems has maximal dynamic range when B32 is 
on the crtEBI genes. Error bars represent standard deviation. (B) Cells expressing 
crtEBI with different RBSs and inducer concentrations. In all systems, when B32 and 
B33 were on the crtEBI genes, uninduced cells are colorless. The visible redness upon 
induction corresponds with the lycopene production in panel B.  
2.3.5 The PLac system produces visible lycopene most quickly 
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 By enabling full repression of pigment production, the time to visible pigmentation 
is determined by the rate of pigment production upon induction, rather than the time for 
growth of large numbers of cells. The RBS and promoter modifications were thus next 
tested for their time to lycopene production upon induction.  
 The three different promoter systems, each with the medium-strength RBS B32 on 
the crtEBI genes, were tested for their time to visible lycopene production upon induction. 
All systems reached the previously established threshold for visible lycopene within four 
hours, and the PLac system had slightly higher lycopene levels than the PBad,weak and PT7LacO2 
systems at all time points (Figure 7A).  
 
Figure 7: Time to response of three different promoter systems.  
(A) Lycopene produced from each promoter system with respect to time. All systems 
reach the 195 (ng/mL)/OD threshold (marked with gray line) within four hours, and 
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the PLac system reaches it the most quickly. Error bars represent standard deviation. 
(B) Cells from each system at different time points.  
 The PLac system produced the most lycopene at all time points, with a final lycopene 
production of 950 (ng/mL)/OD (Figure 7A), ten times more than what was produced after 
18 hours when a small inoculum was used (Figure 6B), which prompted exploration of the 
effects of different inoculum densities. Cultures were inoculated to starting optical 
densities between 0.01 and 0.4 and induced. Cultures inoculated with more cells had higher 
final lycopene levels, though the effects plateaued above an initial inoculum density of OD 
0.05 (Figure 8). Cultures inoculated to optical densities above 0.05 all reached the threshold 
for visible lycopene at approximately the same time (Figure 8).  
 
Figure 8: The effect of inoculation density on lycopene production.  
Fresh media was inoculated with cells expressing crtEBI from PLac to different 
starting optical densities, and 1 mM IPTG was added. Cultures inoculated to an OD 
above 0.05 reached the threshold for visible lycopene production at approximately 
the same time (about 2.5 hours). The faster response time compared to other 
experiments (Figure 7) can be attributed to a decrease in the number of temperature 
excursions in the incubator during the experiment. 
2.3.6 Precursor supplementation reduces time to visible lycopene 
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 To attempt to further decrease the time to visible lycopene production, metabolic 
precursor supplementation was explored. Farnesyl diphosphate (FPP) is the substrate for 
CrtE, the first enzyme in the lycopene-production pathway, and FPP is produced by either 
the nonmevalonate (dxp pathway) or the mevalonate pathway. The dxp pathway naturally 
occurs in E. coli, and the mevalonate pathway can be heterologously expressed in E. coli. 
We have previously shown that addition of the mevalonate pathway increases end-point 
lycopene production by a factor of three25, and we hypothesized that its addition could 
decrease the time to visible lycopene.  
 The fastest responding system (the PLac crtEBI system) was cotransformed with 
either a plasmid containing the mevalonate genes under PBad control (PBad -MEV) or an 
empty control vector (PBad ). PBad -MEV supplementation decreased the time to visible 
lycopene (lycopene > 195 (ng/mL)/OD) to about 1.5 hours (Figure 9A). Interestingly, the 
cells produced lycopene faster and produced more total lycopene when the mevalonate 
pathway was induced at the same time as the crtEBI pathway, rather than when the 
mevalonate pathway was induced during the growth stage to potentially accumulate 
precursors ready for induction of crtEBI. Of note, cells cotransformed with an empty vector 
had a longer time to visible lycopene production than when just the PLac crtEBI vector was 
transformed (about 5.5 hours compared to 3 hours), suggesting that maintenance of a 
second plasmid can significantly decrease pigment production from the first plasmid. 
 Though mevalonate supplementation decreased the time to visible lycopene, it also 
increased the amount of unwanted lycopene in the uninduced state. When PBad -MEV was 
induced in the growth stage, cells contained about 14 times more lycopene compared to 
cells without PBad -MEV, and even when PBad -MEV was repressed in the growth stage, 
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cells still contained over 3 times more lycopene, pushing the lycopene concentration just 
over the preferred threshold for colorless cells (Figure 9B).  
 
Figure 9: Effects of precursor supplementation on lycopene production.  
(A) Normalized lycopene production from the PLac system cotransformed with either 
an empty vector (PBad ) or PBad -MEV, with arabinose induction either during the 
growth phase or at the time of IPTG induction. Addition of the mevalonate pathway 
decreases the time to visible lycopene to 1.5 hours, with the greatest reduction 
occurring when the mevalonate pathway is repressed during the growth stage and 
induced at the same time as the crtEBI pathway. The gray line marks the threshold 
for visibility. (B) Lycopene produced in the growth stage for each system. In the 
uninduced state (no IPTG), lycopene production increases with the presence of PBad -
MEV and further increased when PBad -MEV was induced with arabinose. The gray 
line marks the threshold for perceived colorlessness. All error bars represent 
standard deviation. 
2.4 Discussion  
 In this work, we engineered metabolic pigment pathways to harness them for use 
in a fast-responding whole cell biosensor. Using pigments as reporters can better enable 
sensor use in low-resource settings, since sensor output can be interpreted by the naked 
eye, without any equipment. By engineering cells to be initially colorless, a large inoculum 
of precultured cells can be added to the sample, and the time to pigmentation will be 
determined by the rate of metabolite production rather than the rate of cell growth. 
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However, fully repressing pigment production to achieve an initial “off” state poses unique 
challenges, since small amounts of unwanted protein can catalyze the production of large, 
visible amounts of pigment. Commonly used inducible promoter systems could not 
adequately repress lycopene, which necessitated exploring engineering modifications at 
the transcriptional and translational levels to eliminate unwanted pigmentation. When 
exploring transcriptional modifications, we generated a mutated PBad with 30 times lower 
uninduced levels and a 10 times greater dynamic range, which could be of use in a broad 
range of applications.  
 When characterizing the effects of genetic modifications on RFP and lycopene 
production, we repeatedly encountered the problem that low levels of fluorescent protein 
expression did not correspond with visibly low levels of pigment production. Reducing 
fluorescence by orders of magnitude still yielded promoters with visible uninduced 
lycopene and induced lycopene levels that changed by much smaller factors. The systems 
that could adequately repress lycopene had uninduced fluorescent levels below the plate 
reader’s limit of detection, emphasizing the need for much tighter regulation when using 
pigments instead of fluorescent reporters. When using fluorescent reporters, the value of 
the baseline “off” level is inconsequential as long as the “on” value is distinctly higher. 
However, when using pigment reporters, the enzymatic amplification of low levels of 
expression in the “off” state can confound sensor output, which necessitates focusing on 
reduction of absolute (rather than relative) protein expression. Transcriptional 
modifications made modest improvements in decreasing uninduced lycopene expression, 
but only when the RBS strength of the crtEBI genes was reduced could each system 
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adequately control lycopene production. This suggests that translational modifications are 
perhaps the best starting point in combatting unwanted expression.  
 Differences in RFP and fluorescent induction profiles accentuate the limitations in 
using fluorescent reporters to characterize metabolic pathways. In many systems, as 
inducer was added, RFP production increased (as expected), but lycopene production 
decreased. This reduction in lycopene production upon induction is likely because of the 
added complexities of using metabolite reporters, specifically metabolic precursor 
limitations and toxicity effects at high levels of induction. These differences necessitate 
that when using metabolites as outputs or reporters, all final levels of tuning and system 
characterization must be performed with the final metabolite of interest as the reporter. 
However, despite the limitations of fluorescent reporters, they are useful for first 
approximations of system behavior, especially when assaying for metabolite levels is time-
intensive and costly. 
 Lycopene production varied greatly based on the inoculum density: higher initial 
inocula resulted in higher final titers of lycopene. Previous work in the area of dynamic 
metabolic engineering has demonstrated the usefulness of separating the growth stage and 
metabolite production stage50,51,93. Many of the approaches used in dynamic metabolic 
engineering48,49 can be applied to our biosensor design, since cells must switch from a 
growth to a production phase. However, the requirement of a completely colorless 
preculture necessitates elimination of baseline or leaky pigment expression during the 
growth stage, which is often permitted and can even be beneficial in dynamic metabolic 
engineering efforts.  
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 When optimizing time to visible lycopene upon induction, we encountered a 
tradeoff between low levels of lycopene during the growth stage and fast production of 
lycopene upon induction. The PLac system reached the visibility threshold the most quickly; 
however, the PLac system also had the highest level of uninduced lycopene at the time of 
induction, which may partly account for the faster time to visible pigmentation. Similarly, 
supplementation of metabolic precursors further reduced the time to visible lycopene 
production, but also further increased unwanted lycopene produced during the growth stage 
to a level above the colorless threshold. Though these effects could likely be somewhat 
mitigated by using a more repressible promoter to control the mevalonate pathway genes 
(i.e.: PBad,weak instead of PBad), since the PLac system already has uninduced lycopene levels 
just below the color threshold, it is likely that any level of precursor supplementation will 
push uninduced levels past the threshold.  
 In exploring the effect of metabolic precursor supplementation, we expressed the 
crtEBI genes and the mevalonate pathway genes on separate plasmids. Just by addition of 
a second plasmid (an empty control plasmid), the rate of lycopene production significantly 
decreased, suggesting that addition of a second plasmid places a stress on the cell that can 
alter protein and metabolite production. When the mevalonate genes were expressed on the 
second plasmid, lycopene production dramatically increased despite the limitations of a 
two plasmid system, which emphasizes the power of precursor supplementation. 
Combining the two pathways onto one plasmid would likely further improve the effects of 
precursor supplementation.  
 Though the systems developed should be useful in any biosensing application that 
uses lycopene as a reporter, we acknowledge that the crtEBI genes used in this study are 
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not the only ones used in metabolic engineering applications. In all of our experiments, we 
used crtEBI genes isolated from the bacterium Pantoea ananatis. Most previous work to 
engineer E. coli cells to produce lycopene use either these genes or those from Pantoea 
agglomerans. Though some of the problems we encountered—specifically, high levels of 
uninduced expression and toxicity effects at high levels of induction—could be specific to 
the P. ananatis proteins, work using P. agglomerans genes40 has demonstrated similar 
problems. We also recognize that the visibility thresholds used will likely need to be 
changed based on the form factor of the final application device, but similar approaches 
can be used to develop systems that meet the visibility requirements of different devices. 
 Here we have improved the response time of a previously reported biosensor 
framework by an order of magnitude. We have demonstrated ways to control production 
of the metabolite lycopene, and the approaches used should be generalizable to any other 
metabolite of interest. As the applications of metabolic engineering expand beyond 
traditional chemical production, tight control of output in response to the external 
environment will be necessary. Cells are already being engineered to specifically deliver 
drugs to tumors10,11,94 and to produce different drugs based on what is needed in low-
resource settings 95,96. For both of these applications, it is necessary that cells produce the 
desired compound only in the desired condition—specificity of response based on 
environment is critical. Here, we have demonstrated the ways that transcriptional and 
translational control can be used in combination to engineer response specificity and the 
ways that pathway engineering can increase the rate and intensity of the metabolite 
produced in the “on” state. These same approaches can be used to control production of 
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 DESIGN OF A FAST-RESPONDING, TUNABLE 
ZINC SENSOR 
3.1 Introduction 
 The previous chapter detailed our efforts to completely decouple growth from 
pigment production to decrease the time required to see a visible response upon sample 
addition. Through transcriptional, translational, and metabolic engineering approaches, we 
created cells that fully repress lycopene in the absence of an inducer and produce visible 
lycopene within four hours of sample addition. While this laid the foundation for a fast-
responding whole-cell biosensor, the resulting cells respond only to a standard chemical 
inducer, not to a physiologically relevant compound. To make a usable biosensor, sensor 
cells must be able to respond to different analyte concentrations upon induction. In the 
context of a pigment-based zinc biosensor, this entails engineering cells to be colorless in 
the absence of inducer, and then upon addition of inducer, produce different pigments 
based on the concentration of extracellular zinc. Further, the cells need to respond to 
physiologically relevant zinc concentrations so that they can provide useful clinical data. 
In this chapter, we expand on the inducible systems developed in Chapter 2 by 
incorporating zinc-responsive elements, adding additional pigment pathways, and tuning 
the engineered circuits to respond to specific zinc concentrations.  
 In our group’s previous work developing a zinc biosensor, we repeatedly 
encountered difficulties tuning the sensor to respond to clinically relevant zinc 
concentrations, which is an absolute requirement to making a usable sensor. Most sensors 
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that use bioprospected components respond to concentrations dictated by the natural 
sensor-analyte affinity, which often fall out of the desired response range. The initial 
version of zinc-responsive sensor cells responded to zinc concentrations orders of 
magnitude lower than clinically relevant zinc concentrations. While there are synthetic 
biology tools available to tune sensor response, most are not broadly applicable. Currently, 
the most effective approaches to shift the response curve require extensive protein 
engineering4 or the use of multiple receptors with varied binding affinities for the target 
analyte97,98, which can necessitate bioprospecting for other proteins that bind the target or 
protein engineering to alter the affinity of available receptors. Further, addition of the 
repeated sequences necessary for expression of multiple receptors can destabilize genetic 
constructs99, making plasmids expressing burdensome metabolic pathways much more 
prone to mutations that harm sensor performance.  
Here, we describe the development of a fast-responding whole-cell zinc biosensor 
that accurately quantifies clinically relevant concentrations of zinc in human serum. We 
designed and engineered a library of novel, dual-stimulus-responsive promoters that 
allowed us to decouple pigment metabolism from cell growth and thus produce pigment 
output within four hours of sample addition. We then used transcriptional, translational, 
post-translational, and metabolic control methods to tune which zinc concentrations 
activate different pigment pathways, ultimately shifting the threshold zinc concentrations 
by nearly an order of magnitude compared to our previous proof of principle and into the 
clinically relevant range. The resulting cells can be used to assay unprocessed human 
serum, producing one of three different visible pigments within four hours based on the 
concentration of serum zinc. This work is a major step towards a field-deployable 
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micronutrient biosensor that would impact the treatment of millions of people, and 
demonstrates generalizable strategies for the development of robust and tunable sensor 
cells. 
3.2 Materials and Methods 
3.2.1 Materials 
T4 DNA ligase, T5 exonuclease, Taq ligase, Phusion polymerase, Q5 polymerase, 
and restriction endonucleases were purchased from New England Biolabs (Ipswich, MA, 
USA). E.N.Z.A. Plasmid Mini Kits were purchased from Omega Bio-tek (Norcross, GA, 
USA), and QIAquick PCR Purification Kits and QIAquick Gel Extraction Kits were 
purchased from QIAGEN (Valencia, CA, USA). Lycopene (98%) was purchased from 
Cayman Chemical (Ann Arbor, MI, USA). Sudan I (95%) was purchased from TCI 
America (Portland, OR, USA). 
3.2.2 Strains and plasmids 
Escherichia coli K-12 DH10B (New England Biolabs, Ipswich, MA) was used for 
plasmid assembly. Lambda red recombination100 was used to make a DH10BΔZur strain, 
which was used for all protein and metabolite production. The plasmid pSB3T5, with a 
p15A origin, was taken from the Standard Registry of Biological Parts and used as the 
backbone vector for all plasmids used in the final analysis. The plasmid pSB6A1, which is 
a derivative of the pBR322 plasmid, was obtained from the Standard Registry of Biological 
Parts and used for expression of the mevalonate genes. 
3.2.3 Cloning and construct assembly  
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All constructs were assembled with either Gibson assembly88 or restriction 
endonuclease digestion of components and subsequent ligation and transformation 
following the BioBricks idempotent standard assembly89. LB medium composed of 10 g/ 
L NaCl, 5 g/L yeast extract, and 10 g/L tryptone was used for all cell growth during cloning 
steps. The following antibiotics were used for appropriate selection: tetracycline (15 
µg/mL), chloramphenicol (34 µg/mL), kanamycin (30 µg/mL), and carbenicillin (100 
µg/mL). 
The genes zur and zntR were isolated from previously assembled zinc-responsive 
plasmids47. The coding sequence for Zur from B. subtilus (zurBs) was codon-optimized for 
expression in E. coli, and the gene was synthesized by Eurofins (Louisville, KY). The 
lycopene expression cassette (crtEBI) was amplified from a previously assembled vector79 
that uses the genes from part bba_k274100 of the Registry of Standard Biological Parts. 
The violacein genes vioA, vioB, vioC, vioD, and vioE were amplified from Part 
bba_k274002 of the Registry of Standard Biological Parts. A previously assembled 
arabinose-inducible plasmid expressing the mevalonate pathway79 used genes from the 
plasmid pJBEI-640983, which was obtained from Addgene (Cambridge, MA, USA).  
Lambda red recombination100 was used to make DH10BΔZur, and this strain was 
used for all experiments that assessed response to zinc.   
3.2.4 Cell culture 
For all protein and pigment expression experiments, a modified M9 medium was 
used. A 5× salts solution consisted of 22.5 g/L NaCl, 8.2 g/L KCl, 5 g/L NH4Cl, 19.5 g/L 
MES, 10 g/L β-glycerophosphate and was pH adjusted to 7.4 with 2 M KOH. To remove 
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trace amounts of zinc, each 1 L batch of salts was treated with 1g of Chelex-100 resin. The 
mixture was vigorously stirred for 1 hour, and resin was removed through filtration with a 
0.2 µm filter. The final medium consisted of 1× salts, 2 mM MgSO4, 0.1 mM CaCl2, 0.01% 
thiamine, 1.92 g/L of SC-Ura amino acid mixture (Sunrise Science), and 0.4% of either 
dextrose or glycerol. Medium was sterilized through filtration with a 0.2 µm filter. 
For GFP expression, freshly transformed DH10B colonies were inoculated in 
triplicate into 4 mL of modified M9 medium and grown at 37°C and 220 rpm for 24 hours. 
For pigment expression in the absence of serum, freshly transformed DH10B colonies were 
inoculated in triplicate into 5 mL of modified M9 medium containing the appropriate 
antibiotic, and grown at 37°C and 220 rpm for 18 hours. Cells were concentrated through 
centrifugation and used to inoculate cultures that contained the fresh media with the 
appropriate inducer and zinc concentrations. Each 4 mL culture was inoculated to an OD 
of 0.1 and grown at 37°C and 220 rpm for 4 hours. OD, carotenoid content, and violacein 
content was measured at 4 hours.  
For pigment expression in serum, freshly transformed DH10B colonies were 
inoculated in triplicate into 3 mL of modified M9 medium containing the appropriate 
antibiotic and grown at 37°C and 220 rpm for 8 hours. This culture was used to inoculate 
a 300 mL culture of modified M9 medium containing the appropriate antibiotic, and the 
300 mL culture was grown at 37°C and 220 rpm for 18 hours. Cells were concentrated 
through centrifugation and used to inoculate cultures that consisted of 25% serum, 75% 
modified M9, and the appropriate antibiotics, inducers, and supplemented zinc. Unless 
otherwise specified, 1 mL cultures were inoculated to an OD of 3.0 and grown at 37°C and 
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220 rpm for 4 hours. OD, carotenoid content, and violacein content were measured at 4 
hours. 
3.2.5 Serum processing and zinc measurement 
Pooled human serum was purchased from Corning (Corning, NY). Zinc was 
removed from serum through Chelex-100 treatment. 1g of Chelex 100 resin was added to 
100 mL of serum, and the mixture was vigorously stirred for 2 hr. Zinc concentration was 
measured at the University of Georgia Laboratory for Environmental Analysis. Samples 
were digested with concentrated acid and analyzed on an ICP-MS according to EPA 
method 3052. 
3.2.6 Measurement of optical density and fluorescence 
Optical density of samples was quantified by measuring the absorbance at 600 nm 
either in a ThermoFisher Genesys 20 spectrophotometer with a 10 mm path length or in a 
Biotek Synergy H4 plate reader. When necessary, cultures were diluted to ensure that the 
reading fell within the linear range of the instruments. 1 mL of culture was used for 
spectrophotometer measurements, and 150 µL of culture in a 96 well plate was used for 
plate reader measurements. Calibration curves were made for each instrument and used for 
uniform reporting of optical density. All optical densities reported correspond with those 
taken in the spectrophotometer. 
For GFP quantification, fluorescence at 485 nm excitation and 510 nm emission 
was measured on a Biotek Synergy H4 plate reader. All reported fluorescence values are 
background-subtracted and normalized to optical density.  
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3.2.7 Pigment extraction and quantification 
For carotenoid analysis, either 1 mL or 250 µL of bacterial culture was pelleted at 
18,000 rcf for 5 minutes. Cell pellets were resuspended in 50 µL of ultrapure water. 
Carotenoids were extracted with 1 mL of acetone at 50°C for 15 minutes. A heat block was 
used to maintain temperature and extractions were vortexed every 5 minutes. Cellular 
debris was pelleted at 18,000 rcf for 5 minutes, and 500 µL of supernatant was removed 
for analysis. Carotenoid content was analyzed on a Shimadzu Prominence UFLC using an 
Agilent C18 4.6 mm x 50 mm column with a 5 μm particle size and a Shimadzu photodiode 
array detector. A solvent ratio of 50:30:20 acetonitrile:methanol:isopropanol was used as 
the mobile phase92 and run at a flow rate of 1 mL/min with a 25 μL sample injection 
volume. Absorption was detected at 471 nm. Retention times and peak intensities were 
compared to analytical standards spiked into control extractions from DH10B cells. 
For violacein analysis, either 1 mL or 300 µL of bacterial culture was pelleted at 
18,000 rcf for 5 minutes. Cell pellets were resuspended in 50 µL of ultrapure water. 
Violacein was extracted with 40 µL of water-saturated butanol. The mixtures were 
vortexed for 5 minutes at room temperature and then centrifuged at 18,000 rcf for 5 
minutes. The butanol layer was removed and recentrifuged at 18,000 rcf for 5 minutes. 15 
µL of the butanol extraction was removed for analysis and added to a 384 well plate. 
Absorbance at 585 nm was measured on a Synergy H4 plate reader. All reported values are 
background subtracted, using a butanol extraction of non-engineered E. coli cells as the 
blank.  
3.2.8 Protein mutagenesis experiments 
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 For undirected mutagenesis of zur, error-prone PCR was used to introduce 
mutations at a target rate of 2 amino acids/coding sequence using the protocol described in 
Wilson and Keefe101 with magnesium and manganese concentrations adapted to be 2 mM 
MgCl2 and 0.25 mM MnCl2. 15 cycles were run with a denaturation step of 30 sec at 95°C, 
an annealing step of 60 sec at 51°C, and an extension step of 5 min at 68°C. Mutated 
sequences were inserted into a GFP expression plasmid through Gibson assembly, and 
plasmids were transformed into DH10BΔZur cells and grown on modified M9-agar plates 
with 1 μM zinc at 37°C. After 24 hours, plates were visually inspected, and green colonies 
were streaked onto modified M9-agar plates containing 20 μM zinc and incubated at 37°C. 
After 18 hours, plates were analyzed, and cells that were visibly green on 1 μM plates and 
visibly colorless on 20 μM plates were inoculated. Plasmids were isolated from these cells, 
sequenced, and used for a more thorough analysis of zinc response.  
 For site-directed mutagenesis of Zur, eight residues were chosen for saturation 
mutagenesis based on their proximity to the zinc-binding residues or role in the dimer 
interface. Using primers for NNK mutagenesis (Eurofins) of the specified residue, a GFP-
expression plasmid was assembled, transformed into DH10BΔZur cells, plated on modified 
M9 plates, and grown at 37C for 18 hours. 96 individual colonies were inoculated into 150 
μL of modified M9 containing 1 μM zinc in a 96 well plate and grown at 180 rpm and 
37°C. After 12 hours, fluorescence and OD were measured, and 7.5 μL of each culture was 
added to 140 ul of modified M9 media containing 20 μM zinc. After 6 hours, GFP and OD 
were measured.  
3.3 Results 
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3.3.1 Synthetic promoters to separate chemical production from cell growth 
Our previous efforts to engineer diagnostic zinc sensor cells were plagued by long assay 
times, construct instability, and poor test interpretability, which needed to be overcome in 
order to make a potentially deployable diagnostic. To accomplish this goal, we sought to 
decouple pigment production from cell growth by using a small molecule inducer as a 
master regulator to control expression of all pigment pathways. During the pre-assay 
inoculum production stage (in the absence of inducer), cells would be colorless, which 
would decrease the metabolic burden on cells during the growth phase and thus improve 
cell viability and genetic circuit construct stability48,50,79,93,102. A large inoculum of these 
cells could then be added to the sample, and a standard inducer (such as IPTG or arabinose) 
would turn the color synthesis system “on”, leaving zinc-responsive elements to control 
pigment production. The assay time would then depend only on the pigment biosynthesis 
rate (Figure 10), and not the time needed for generation of visible biomass from a small 
(colored) inoculum as in our proof-of-principle work. This would also improve test 
interpretation (since colorless cells will indicate an incomplete or nonfunctional test).  
 
Figure 10: Schematic illustrating the overall design of a dual-input system that 
decouples cell growth from pigment production.  
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A large culture of colorless cells is grown to saturation. These cells are added to fresh 
medium or to a serum sample at a density high enough that cells are visible, and a 
small-molecule inducer is added to activate the color-response circuit. After a short 
incubation (approximately 4 hours), different pigments are produced to indicate 
different zinc concentrations 
 To engineer a system in which pigment production is controlled by both a standard 
inducer and zinc, we designed dual-input synthetic promoters with operator sites for both 
the inducer’s cognate transcriptional regulator (such as LacI) and for the zinc-responsive 
repressor Zur. During the pre-assay inoculum production stage, LacI (for example) binds 
to its cognate operator and prevents expression of downstream pigment production genes. 
IPTG addition should alleviate this repression, with gene expression then solely controlled 
by Zur, a repressor that binds to its cognate operator in the presence of zinc. Ideally, 
expression from this promoter would only occur at very low zinc concentrations (Figure 
11A). The transcriptional regulators AraC and T7 RNA polymerase have different 
regulatory mechanisms, but could enact the same logical function (Figure 11B,C).  
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Figure 11: Circuit diagrams and schematics depicting the design of a dual-input 
promoters to regulate production of the violacein pathway genes.  
 (A) LacI/IPTG controlled circuit. During the pre-assay culture stage, LacI represses 
pigment production. IPTG is added as an inducer to alleviate LacI repression, and 
the pathway genes are then controlled by Zur. Zur is a transcriptional repressor that 
is only active when bound to zinc; thus violacein will only be produced in low zinc 
conditions. (B) AraC/arabinose controlled circuit. During the pre-assay culture stage, 
AraC represses pigment production. Arabinose is added as an inducer to activate 
AraC (switching AraC from a repressor to an activator), and the pathway genes are 
then controlled by Zur, which binds to its operator in the presence of zinc. (C) T7 
RNAP/LacI/IPTG controlled circuit. During the pre-assay culture stage, LacI 
represses expression of both T7 RNA polymerase and any leaky expression from the 
synthetic promoter. IPTG is added as an inducer to alleviate LacI repression, and T7 
RNAP is produced. Pathway genes are then controlled by Zur, which binds to its 
operator in the presence of zinc.  
We created a first generation of dual-input promoters (referred to as PLacZnu,1, 
PBadZnu,1, and PT7Znu,1), by adding a single Zur operator site downstream of a standard 
inducible promoter (Figure 12A, Table 2). Addition of operator sites has been successfully 
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used in previous efforts to make promoters controlled by two inputs45,46,103,104, and while 
fluorescent characterization showed that these first-generation hybrid promoters all 
respond to both IPTG and zinc, all promoters showed high levels of baseline, uninduced 
protein expression (Figure 12B). Zur’s operator sequence includes a -10 σ70 RNA 
polymerase binding domain that is heavily conserved across Zur-regulated promoters105, 
so this leakiness is likely caused by unintentional introduction of a promoter element. To 
decrease this unwanted expression, we engineered a second generation of PLac- and PT7-
based promoters that included additional LacI operators downstream of the Zur operator 
(Figure 12A, Table 2). The second generation of hybrid promoters all showed decreased 
uninduced expression and improved dynamic range (Figure 12B).  
 
 
Figure 12: Design and characterization of synthetic dual-input promoters. 
(A) Promoter architecture for the library of novel promoters. The -10 and -35 σ70 
binding domains are marked, and lac and zur operator sites are shown in yellow and 
blue, respectively. For the PBadZnu promoter, the -10 binding domain is not explicitly 
marked because it is embedded in the Zur operator site, and the green box indicates 
the entire PBad promoter sequence that is upstream of the -35 binding domain. For 
the PT7 variants, the consensus T7 RNAP binding domain is marked in gray. Table 2 
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contains annotated promoter sequences for all constructed promoters. (B). 
Fluorescent characterization of all engineered promoters. Engineered promoters 
were used to control production of eGFP. Ideally, eGFP should only be produced in 
the +inducer/-zinc state, as indicated by the Pideal values. Labels on the vertical axis 
correspond with the promoters depicted in (A). IPTG was used to induce both the 
PLac- and PT7-based circuits, arabinose was used to induce the PBad-based circuit, and 
when indicated, zinc was added to a concentration of 20 µM.  
Table 2: Sequences of all dual-input promoters used in this study. 
The sequences are color coded according to the schematic in Figure 12. Lac operator 
sites are highlighted in yellow; the sequence of AraC- PBad promoter is highlighted in 
green; Zur operator sites are highlighted in blue, and the -10 σ70 binding site is 
underlined and italicized. For all PLac and PBad variants, the -10 and -35 σ70 binding 
sites are bolded and underlined. For all PT7 variants, the consensus T7 promoter 




































We determined the best-responding promoter of each class by calculating the 
relative change in fluorescence caused by inducer and zinc addition (Table 3), and then 
used these selected promoters to control production of the violacein production pathway. 
A starter culture of uninduced cells that had been grown overnight was used to inoculate 
tubes containing fresh medium, the appropriate inducer, and different concentrations of 
zinc. Though all systems showed some level of induction, the PLac-based system 
outperformed the others, as it had visually undetectable violacein production in the 
overnight culture and the highest level of induced violacein production (Figure 13). 
Table 3: Fold change of all characterized promoters in response to the inducer and to 
zinc. 
Promoter 
Response to inducer 
(fold change) 
Response to zinc 
(fold change) 
PZnuLac,1 6.31 77.0 
PZnuLac,2A 188 24.8 
PZnuLac,2B 73.7 52.1 
PBadZnu,1 3.10 107 
PT7Znu,1 25.0 0.867 
PT7Znu,2A 85.37 143 




Figure 13: Violacein production from the best-responding hybrid promoters.  
The best-responding promoter from each group was selected to control production of 
the violacein pathway genes. A starter culture was grown without any inducer or zinc, 
and then used to inoculate cultures that contained the appropriate inducer and 
different concentrations of zinc. Error bars indicate standard deviations. Images 
below the graph show representative cell pellets from each condition. 
3.3.2 A multi-colored, fast-responding zinc sensor 
Using the optimized PLac-based violacein circuit, we constructed multi-color zinc-
responsive sensor cells by incorporating metabolic pathways from the carotenoid pathway, 
specifically those to produce the red pigment lycopene and the orange pigment β-carotene. 
We used LacI/IPTG to control expression of the lycopene production pathway and the zinc-
responsive activator ZntR to control expression of the enzyme CrtY, which converts 
lycopene into β-carotene (Figure 14A). Upon IPTG induction, cells will always produce 
lycopene, but cells should only appear red at intermediate zinc concentrations: at low zinc 
concentrations, the more intense pigment violacein overwhelms lycopene and cells appear 
purple, while at high zinc concentrations CrtY converts all lycopene into β-carotene and 
cells appear orange. The mevalonate pathway genes (which produce the precursor to the 
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carotenoid pathway) were expressed from PBad to increase the rate and intensity of 
carotenoid production.  
 As designed, the implemented engineered cells turn one of three colors based on 
the zinc concentration. After overnight growth (with no inducer), cells are visibly colorless 
and have no detectable violacein or carotenoid. When these cells are used to inoculate 
medium containing IPTG and different concentrations of zinc, cells appear visibly purple, 
red, or orange (Figure 14B) after four hours of culture.  
 
Figure 14: Initial multi-color sensor cells.  
(A) Circuit diagram and schematic depicting the design of the three-color circuit. 
During the pre-assay culture stage, LacI represses all pigment production by 
repressing PLacZnu,2B (which controls violacein production) and PLac (which controls 
lycopene production). IPTG alleviates LacI repression, activating the pigment 
production module indicated by the dashed box in the schematic. The crtEBI genes, 
which control lycopene production, are produced at all zinc concentrations. In low 
zinc concentrations, violacein is produced, overpowering lycopene production and 
leading to visibly purple cells. At intermediate zinc concentrations, Zur binds zinc 
and represses violacein expression, leading to visibly red cells. At high zinc 
concentrations, ZntR also binds zinc and activates production of CrtY, which 
converts lycopene to β-carotene, leading to visibly orange cells. (B) Pigment 
quantification and visualization of sensor cells that were induced with IPTG and 
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grown for four hours. At low zinc concentrations, cells produce violacein and 
lycopene and appear visibly purple. Cells grown in zinc concentrations between 0.2 
and 10 µM are visibly red. At high zinc concentrations, β-carotene production 
overpowers lycopene production, and cells appear visibly orange. The dotted line 
indicates the threshold for visible violacein. Error bars indicate standard deviations. 
The bracket indicates the range of physiologically relevant zinc concentrations 
corresponding with cells grown in 25% human serum. Ideally, cells should appear 
three different colors within this bracketed concentration range.  
To better enable objective color assessment, we set thresholds for color 
classifications. We surveyed ten people to ask how they would classify the colors of cells 
that contained different levels of violacein, lycopene, and β-carotene (Figure 15). Based on 
these results, cells that contained OD-normalized violacein > 0.2 are considered purple, 
and cells that contain OD-normalized violacein < 0.2 are classified based on the dominating 
carotenoid: either red or orange, based on whether cells contain primarily lycopene or 
primarily β-carotene, respectively.  
 Though the initial sensor cells respond to a wide variety of zinc concentrations, the 
concentration range is far wider than the clinically relevant range of zinc concentrations. 
To meet the requirements for in-field nutrition testing, an assay should require both small 
amounts of serum and minimal sample processing, so we aimed to run our test in a 25% 
serum sample. Population data show that serum zinc concentrations fall between 2 and 20 
μM24, so a test run in 25% serum must produce distinct colors across a range of 0.5 to 5 
μM zinc. Across this range, all sensor cells produced primarily lycopene and are classified 
as red according to predetermined color thresholds. To make a field-deployable sensor, we 
thus needed to shift both the zinc concentration that triggers the purple-to-red color 
transition and the concentration that triggers the red-to-orange color transition, overall 
narrowing the response range by an order of magnitude.  
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Figure 15: Color classification of cells with different pigment concentrations.  
(A) Fourteen strains expressing different levels of violacein, lycopene, and beta-
carotene were presented to ten different people one at a time in a random order, and 
each person was asked to match the perceived color of the each samples to different 
colors on a spectrum. (B) The color spectrum used in the survey to assess color. RGB 
quantification of cell pellets expressing only violacein, only lycopene, and only β-
carotene was used to set the far left (A), middle (C), and far right (E) colors, 
respectively. The intermediate color (B) was set by averaging the RGB values of (A) 
and (C), and the intermediate color (D) was set by averaging the RGB values of (C) 
and (E). Each sample was classified as one of five colors based on the overall survey 
consensus. We deemed cells classified as (A) or (B) as “purple”, cells classified as (C) 
as “red”, and cells classified as (D) or (E) as “orange”. (C) Pigment quantification of 
the fourteen strains and determination of quantitative color thresholds. Cell pellets 
contain pooled samples from biological triplicates. OD-normalized concentrations of 
violacein, lycopene, and β-carotene were quantified. To better enable color 
thresholds, we reduced carotenoid quantification into a single variable: the fraction 
of total carotenoid produced that is β-carotene. Error bars indicate the standard 
deviation. Symbol colors and shapes indicate survey results. We used these data to set 
quantitative color thresholds. Cells with OD-normalized violacein > 0.2 are 
considered “purple”. Cells with OD-normalized violacein < 0.2 are considered “red” 
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if the fraction of β-carotene is < 0.5, and “orange” if the fraction of β-carotene is > 
0.5.  
3.3.3 Rational tuning of color switch points 
We first focused on shifting the purple-to-red response point so that higher zinc 
concentrations are required to shut down violacein production. Both colorimetric and 
fluorescent characterization show that expression of PLacZnu,2 shuts off by 200 nM, and we 
aimed to shift this by an order of magnitude to a concentration between 1 and 3 µM.
 We explored several strategies to increase the threshold concentration that activates 
the purple to red color transition. We first tested whether reducing the amount of Zur in the 
system could shift the transition point to higher concentrations. Decreasing Zur expression 
through ribosomal binding site (RBS) modifications on Zur had little to no effect on Zur’s 
switch point and instead led to increased protein production at all zinc concentrations 
(Figure 16).  
 62 
 
Figure 16: Effect of Zur levels on zinc response.  
(A) Genetic circuit used to test the effect of RBS modulation on response to zinc. Zur 
is constitutively expressed from the promoter PJ23117, and the RBS of Zur is varied. 
(B) Fluorescent characterization showing the effect of Zur levels on expression from 
PLacZnu,2. Compared to the baseline Zur with an RBS strength of 2500, Zur with a 
decreased RBS strength of 500 leads to higher eGFP production at all zinc 
concentration and minimal decrease between 1 and 20 µM zinc. Increasing the RBS 
strength to 5600 had no apparent effect on PLacZnu,2 expression. RBS sequences were 
taken from the standard registry of parts, and their relative strengths were quantified 
with the RBS calculator90. 
We next attempted to use a heterologous zinc-responsive repressor taken from 
Bacillus subtilis (termed ZurBs) to control expression of two B. subtilis promoters that 
demonstrate different in vitro responses to zinc depletion106. We placed these operator sites 
downstream of a standard E. coli promoter, and fluorescent characterization shows that 
ZurBs fully repressed expression from both tested promoter sequences before 1 µM zinc 
(Figure 17).  
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Figure 17: Response of heterologous Zur to added zinc.  
(A) Genetic circuit and schematic depicting regulatory mechanism of B. subtilis’s Zur 
(ZurBs). ZurBs is constitutively expressed from the promoter PJ23117, and when ZurBs 
is bound to zinc, it binds to its cognate operator site to repress transcription. (B) 
Sequences of promoters that controlled by ZurBs. Two different ZurBs operator sites, 
taken from either the PznuA or PfolEB of B. subtilus, were cloned downstream of a Lac-
inducible promoter. (C) Fluorescent characterization of ZurBs regulation. Expression 
from both ZurBs-responsive promoters shuts off by 1 µM zinc.  
We then explored protein engineering strategies to engineer an E. coli Zur mutant 
with a decreased affinity for zinc that maintained a high dynamic range (Figure 18). We 
mutagenized Zur through both error-prone PCR (EP-PCR) of the entire gene and through 
saturation mutagenesis of rationally-selected residues near Zur’s zinc-binding pockets and 
dimerization domains. The best-responding mutants had relatively high GFP production at 
1 μM zinc, but had only 2-3 fold differences in expression between 1 and 30 μM zinc, far 
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lower than the nearly 100-fold expression differences between 0 and 1 μM zinc 
characteristic of wild-type Zur.  
 
Figure 18: Zur mutagenesis to move Zur response point.  
(A) Plan for untargeted Zur mutagenesis and screening. Error-prone PCR was used 
to introduce mutations into the coding sequence of Zur, as indicated with the asterisk. 
Transformants were plated on M9-agar plates that contained 1 µM zinc and grown 
overnight. Visibly green colonies were selected and streaked onto M9-agar plates 
containing 20 µM zinc. Visibly white colonies were then selected for further screening. 
(B) Fluorescent characterization of mutagenesis “hits”. Of the over 10,000 colonies 
screened, plasmids were isolated from the three initial “hits”, sequenced, and more 
thoroughly characterized. All mutants showed decreased expression between 1 and 
30 µM zinc, but the fold changes were relatively small. The previously characterized 
mutant C103S105 cannot bind zinc and was used to control for decreased expression 
caused solely by addition of zinc. (C) Target residues for site-directed mutagenesis of 
Zur. Using a crystal structure of Zur bound to DNA (PDB ID 4MTD)105 and PyMol 
software107, seven amino acid residues were selected for saturation mutagenesis, 
based on either their proximity to the zinc-binding domains or their role in the protein 
dimerization domain. For each residue, 96 colonies were inoculated into minimal 
media containing 1 µM zinc and grown overnight. Then, this starter culture was used 
to inoculate media with 20 µM zinc and grown for 12 hours. We set thresholds for 
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“hits” if the OD-normalized eGFP fluorescence of cells grown in 1 µM zinc was both 
two-fold higher than cells grown in 30 µM zinc and ten-fold greater than the 
autofluorescence of untransformed cells. (D) Results of mutagenesis. Of all mutants 
formed, only a single colony met the requirements specified in (C). This mutant was 
sequenced, and the mutation (L142P) was the same mutation found in the EP-PCR 
mutagenesis experiments. 
 Redesigning regulatory circuit architecture proved much more effective and 
enabled us to successfully move Zur’s effective response point. Instead of altering Zur’s 
activity, we engineered a system such that Zur is only produced (and thus only available 
for repression) when zinc is present. Building off of a previously described “inverter”26, 
we used the zinc-responsive activator ZntR to control Zur expression from the promoter 
PzntA, creating a system that produces more Zur at higher zinc concentrations (Figure 19A). 
Thus, even if Zur is effectively all bound to zinc by 0.2 μM and thus in a repressive mode, 
by modulating the amount of Zur present we can control how much repression of PLacZnu,2 
there is. Expression from PLacZnu,2 should thus decrease more slowly with added zinc, and 
at some threshold zinc concentration, expression from PLacZnu,2 should be fully repressed. 
This threshold zinc concentration can be rationally tuned by varying the RBS and ssrA 
degradation tag on Zur: systems with low levels of Zur will require more transcription from 
PzntA and thus more zinc to shut off violacein expression.  
We made a library of sensor cells with this circuit design that turn off expression 
from PLacZnu,2 at varied zinc concentrations while also maintaining high dynamic ranges. 
We designed RBSs with varied strengths using the RBS calculator78 and used ssrA 
degradation tags with different relative degradation rates108. Fluorescent protein 
characterization shows that variation in expression of Zur from PzntA enables systems that 
fully repress expression from the PLacZnu,2B promoter at zinc concentrations between 0 and 
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30 μM (Figure 19B). Cells show up to 200-fold expression differences between 1 and 20 
μM, far higher than the 3-fold changes seen in the best-responding Zur mutants. When 
these systems control violacein production, threshold zinc concentrations are slightly lower 
than the threshold concentrations seen in fluorescent characterization, but the Zur “off” 
point still ranges between 0 and 5 μM zinc (Figure 19C, Figure 19D). We chose the circuit 
that shut off violacein expression between 2 and 5 μM as the best-responding system and 
used this for all further testing. 
 
 
Figure 19: Tuning color thresholds with an inverter.  
(A) Circuit diagram and schematic depicting “inverter” method to modulate 
PLacZnu,2B expression. During the pre-assay culture stage, LacI represses all pigment 
production. Upon IPTG addition, the activator ZntR controls expression of Zur: 
increasing concentrations of zinc correspond with increased amounts of Zur, which 
leads to decreasing expression from PLacZnu,2B. The RBS and ssrA tag modulate the 
amount of Zur produced and thus the amount of zinc needed to activate full Zur 
repression. (B) Fluorescent characterization of Zur inverter circuits. A library of 
circuits was assembled with different relative levels of Zur. RBS values are the 
predicted relative RBS strength, and ssrA values indicate the relative amount of 
protein that remains (ssrA strength = 1 corresponds with no added degradation tag, 
and ssrA strength = 0.01 corresponds with the strongest degradation tag). Decreasing 
Zur expression levels correspond with cells that shut off expression at higher zinc 
concentrations. (C) Visual assessment of cells with tunable violacein expression. 
Overnight starter cultures were added to fresh media that contained IPTG and 
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specified zinc concentrations and grown for four hours. (D) Violacein quantification 
of inverter constructs. OD-normalized violacein was quantified for the cells depicted 
in Figure 3C. The dotted line indicates the threshold for visible violacein. Errors bars 
indicate standard deviation. 
We incorporated the optimized violacein-control pathways into the three-color 
expression plasmids, and then tuned the red-to-orange transition point by varying the 
expression levels of CrtY, the enzyme that converts lycopene to β-carotene (Figure 20A). 
This tuning approach is analogous to the approach we used to tune the purple-to-red 
transition point, but we modulated expression levels of an enzyme, rather than a 
transcriptional regulator. Cells with lower expression levels of CrtY require a higher 
concentration of zinc to produce sufficient CrtY to mediate the red to orange color change 
and thus should appear red over a larger range of zinc concentrations.  
Through these tuning approaches, we created a suite of three-color sensor cells with 
tunable zinc thresholds. We initially performed tests in media that contained glucose as the 
carbon source (Figure 20B), and in these cells, violacein largely overpowered carotenoid 
expression and created murky colored intermediates. When we instead used glycerol as the 
carbon source, cells show reduced violacein expression and increased carotenoid 
expression. They then appear distinctly purple, red, and orange (Figure 20C), and have 
purple “off” points between 1 and 2 µM zinc. Cells with the lowest CrtY expression do not 
turn orange over the range of zinc tested, and cells with the highest CrtY expression 
transition from red to orange between 0 and 1 µM zinc. The best responding cells, which 
have intermediate CrtY expression, turn from red to orange at approximately 5 µM zinc, 
enabling sensor cells that meet the defined criteria of producing three different colors 
between 0.5 and 5 µM zinc. 
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Figure 20: Multi-color sensor cells that respond to physiologically relevant zinc 
concentrations.  
(A) Circuit diagram and schematic depicting the design of tunable sensor cells. 
During the pre-assay culture stage, LacI represses all pigment production. IPTG 
addition activates the pigment production stage, which is indicated by the dashed box. 
ZntR controls expression of both Zur and CrtY. At a threshold zinc concentration, 
Zur will repress expression of the violacein pathway, leading to cells that are red at 
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intermediate zinc concentrations. Increasing amounts of zinc also lead to increased 
amounts of CrtY, which converts lycopene to beta-carotene. Modulation of the RBS 
and ssrA tag on CrtY can be used to tune the red to orange transition point. (B) 
Pigment quantification and visualization of three-color sensor cells grown in minimal 
medium containing glucose. All sensor cells have tunable color transition points, but 
high baseline violacein production and low overall carotenoid expression leads to 
murky-looking cells. (C) Pigment quantification and visualization of sensor cells 
grown in minimal medium containing glycerol. All sensor cells have violacein “off” 
points between 1 and 2 µM, and the lycopene to β-carotene transition points vary 
based on the expression levels of CrtY. The best performing sensor cells have 
moderate CrtY expression and are visibly purple, red, and orange across a 
physiologically relevant range of zinc concentrations. The dotted line indicates the 
threshold for visible violacein. 
3.3.4 Assessment of physiologically relevant zinc concentrations in human serum 
 We next used these cells to assess zinc concentration in real human serum. We first 
used an inducible lycopene circuit to show that cells are metabolically active in serum as 
long as they are inoculated to a sufficiently high OD (Figure 21).  
 
Figure 21: Effect of serum percentage and inoculation density on cell growth and 
pigment production.  
(A) Circuit diagram of construct used to test metabolic activity. The crtEBI genes, 
which produce the red pigment lycopene, are controlled by an IPTG-inducible 
promoter. (B) Effect of serum percentage and initial inoculation density on terminal 
OD. For cells to grow in increasing amounts of serum, cultures must be inoculated to 
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higher starting densities. Data points falling below the dotted gray line indicate that 
cells had negative changes in OD, which could indicate cell lysis. (C) Effect of serum 
percentage and initial inoculation density on terminal lycopene production. When 
grown in serum, if cultures are inoculated to a sufficiently high initial OD, cells 
produce more OD-normalized lycopene than cells grown without serum. 
Based on preliminary experiments (data not shown) that showed stronger color 
production at even higher inoculation densities, we inoculated a very high concentration of 
the initial sensor cells (ODinitial = 3.0) into media containing 25% human serum that had 
different zinc concentrations. Cells produced different pigments based on the concentration 
of zinc in the sample, turning either purple, red, or orange across a physiologically relevant 
range of zinc concentrations (Figure 22).  
 
Figure 22: Pigment quantification and visualization of sensor cells grow in 25% 
serum with IPTG and specified zinc concentrations.  
Assessment was performed four hours after inoculation. Cells are visibly purple, red, 
or orange across a range of physiologically relevant zinc concentrations. The dotted 
line indicates the threshold for visible violacein. 
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 Though we focused on equipment-free test interpretation, cell color results could 
also be assessed quantitatively, which would eliminate potential subjectivity and variability 
and could enable more precise and reliable assessment of serum zinc values. Using the 
RGB values from the color bar used in the survey to assess color thresholds (Figure 15), 
we developed linear relationships between RGB values and perceived color. We then 
quantified the RGB values of photos of cell pellets and calculated a “color score” that 
indicates the cell’s relative color (with purple = 0 – 1.5, red = 1.5 – 2.5, and orange = 2.5 
– 4) (Figure 23 A-C). Color scores increase with increasing zinc concentrations, and based 
on set thresholds, cells grown in the physiologically relevant concentration range of 0.5 – 
5 µM zinc are either purple, red, or orange (Figure 23D). Though we used color scores only 
for classification of colors into one of three bins, a calibration curve that relates color score 
to zinc concentrations could enable more precise zinc quantification. 
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Figure 23: Quantitative color assessment of cells grown in human serum. 
(A) Colors and color scores that correspond with purple, red, and orange cells. Color 
classifications are based on the color spectrum shown in Figure 15. (B) Plot of the 
RGB values corresponding with the color bar shown in (A). From these data, we 
determined relationships to relate the raw color value of each channel to the color 
score that describes whether cells are purple, red, or orange. The x-axis represents 
color, with 0 and 1 corresponding with purple cells, 2 corresponding with red cells, 
and 3 and 4 corresponding with orange cells. (C) Example of photo processing 
pipeline. The average RGB values of each cell pellet are determined with Adobe 
Photoshop. For each of the red, blue, and green values, a color score is calculated 
using the correlations shown in (B). These three numbers are averaged to produce a 
single overall color score. (D) Quantitative color assessment of sensor cells. Using 
RGB values taken from images of cell pellets, a color score was calculated for cells 
grown in each zinc concentration. Data points show the average of three biological 
replicates, and error bars indicate standard deviation. 
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3.4 Discussion 
We have demonstrated significant steps in the development of a pigment-based 
biosensor for micronutrient testing and have developed generalizable strategies to decrease 
the time to response, increase cell stability, and tune the response range that can be applied 
to the development of other responsive microbial systems. The final sensor cells turn either 
purple, red, or orange to indicate whether a sample has dangerously low, borderline, or 
healthy levels of serum zinc. The test can be interpreted visually by matching colors to a 
color bar or quantitatively by simply taking a picture of the cells and determining RGB 
values. Compared to previous proof-of-principle work, we reduced assay time by nearly 
an order of magnitude, meeting a critical requirement for in-field micronutrient assessment. 
We also tuned the sensor response point by an order of magnitude, reducing the 
colorimetric response range to a clinically relevant range of 0.5 – 5 µM.  
 The developed sensor cells can serve as the foundation of a zinc diagnostic that 
meets the requirements for a field-deployable micronutrient assay18. Tests produce results 
quickly (within the typical time allocation for an in-home visit during a nutritional survey 
campaign), require minimal equipment, and require minimal sample processing. Serum 
could be isolated from blood with a low-cost, portable, paper-based centrifuge109, and 
added to lyophilized sensor cells. After a four-hour incubation, the user could assess test 
results visually or with a camera phone that contains a simple photo processing program. 
This test would allow zinc assessment to be incorporated into standard public health 
surveys and thus provide governments and aid organizations with the information needed 
to efficiently implement zinc supplementation programs. 
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 More broadly, the sensor cells we created can serve as a platform for the 
development of other sensor cells that produce chemical outputs. In the final sensor cells, 
a single transcription factor mediates multiple metabolite production pathways: ZntR 
directly mediates production of β-carotene and indirectly mediates production of violacein 
by controlling expression of Zur, which is effectively a constitutive repressor. By replacing 
PzntA with a different metabolite-responsive promoter, one could easily make a pigment-
based biosensor for a different target metabolite. E. coli has a host of metabolite-responsive 
promoters46, enabling easy production of sensors for a range of metabolites. Transcription 
factors and regulatory pathways from other organisms can also be expressed in E. coli, 
further broadening the scope of biosensor development. For applications outside of 
pigment-based biosensing, other metabolic pathways could replace the pigment expression 
pathways to enable production of a desired chemical upon sensing a threshold 
concentration analyte. 
 Recently developed prototyping tools can help facilitate easy incorporation of new 
metabolic pathways into this sensing framework. Cell-free expression (CFE) systems, 
which use bacterial protein extract to implement genetic networks, can be used to rapidly 
prototype metabolic pathways to determine the optimal relative expression levels of each 
pathway enzyme71,72. While CFE systems have garnered attention for use as 
biosensors16,110, for applications that require sustained and scalable chemical production, 
living cells are the more advantageous chassis, and CFE systems are most useful as tools 
to rapidly explore the design space. 
While we were able to effectively shift Zur’s response point, our tuning strategy 
sacrificed Zur’s original sharp, step-like response (which would have enabled more 
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discrete color changes) for a linear response over the concentration range of interest. 
Incorporation of positive feedback loops and more extensive protein engineering efforts 
could be used to create systems that have both shifted response thresholds and cooperative, 
switch-like responses. Further optimization could also involve redesigning the system to 
allow more orthogonal control of expression levels of specific proteins. To alter levels of 
both Zur and CrtY, we used protein degradation tags because of their effectiveness in 
decreasing protein levels. However, using degradation tags to control multiple regulator 
proteins could introduce competition for proteases and thus inadvertently couple 
expression levels of the two proteins. Alternative approaches for more precise, orthogonal 
tuning could rely solely on modulating RBS strength.  
 As the applications of biosensing expand to include not just sensors, but living 
therapies, engineering cells to deliver diverse types of payloads upon sensing target 
molecules will be critical. Responsive bacterial therapies have already been developed for 
treatment of cancer10,11, metabolic disorders12,13, and inflammation14, and cells that produce 
complex chemicals upon target recognition could have an even greater impact on disease 
treatment. The presented approaches for incorporating chemical production into biosensors 
in a robust and tunable fashion can help to enable a new generation of bacterial sensors to 
meet the need for responsive chemical delivery. 
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 POINT-OF-CARE BIOMARKER 
QUANTIFICATION IN CELL-FREE DIAGNOSTICS 
4.1 Introduction 
The previous two chapters described our efforts towards a field-deployable whole-
cell biosensor for in-field zinc assessment. We created a biosensor that produces multiple 
pigments that correspond with different concentrations of serum zinc, and the tests are 
interpretable within four hours of sample addition. However, engineering a field-
deployable test still requires developing protocols for cell lyophilization, packaging, 
reconstitution, and point-of-care incubation. Cell-free systems, which use bacterial protein 
extract for transcription and translation, have already been demonstrated to be field-
deployable: they can be lyophilized on paper and rehydrated in the field, they produce 
colored outputs quickly, and they require very small reaction volumes. Because of these 
advantages, we explored whether we could use cell-free expression systems to create a 
more field-friendly zinc sensor.  
In recent years, cell-free expression (CFE) systems have dramatically expanded the 
scope and applications of synthetic biology56. CFE systems have brought drug 
manufacturing, vaccine production, and disease diagnoses from labs and clinics into the 
field, where production or testing can be performed on-demand and on-site15,110. Low cost, 
ease of use, and ability to be stably stored and shipped make CFE systems appealing for 
use in low-resource settings. CFE systems have been particularly useful in the development 
of fast and sensitive diagnostic tools for infectious diseases, including Ebola and Zika 
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viruses16, with other technologies expanding on these advances74,75,111. However, to date, 
low-resource CFE diagnostics have been limited to diseases that have nucleic acid 
biomarkers.  
 Differences in levels of other biomarkers, such as ions, metabolites, and proteins, 
indicate a wide variety of important diseases and conditions, including micronutrient 
deficiencies112-114. Unlike diagnosing infectious diseases, which requires determining only 
whether a specific pathogen is present, diagnosing these conditions can necessitate 
discriminating biomarker levels across a small range of concentrations. The ability to sense 
small molecules and ions in cell-free reactions76-78 suggests that the benefits of CFE 
diagnostics could extend beyond infectious diseases. However, the potential applications 
of low-resource CFE measurement of biomarkers in relevant samples (such as serum) are 
limited to detection, rather than quantification, in large part because equipment-free 
quantification methods (i.e., the ability to read measurements with the naked eye) do not 
exist. Moreover, variability in the components of samples can affect the readouts of even 
sophisticated analytical instrumentation, a phenomenon known as “matrix effects”. These 
matrix effects can cause inaccurate or irreproducible results, and are prominent in CFE 
reactions, thus precluding the use of defined reference standards (e.g., pure chemical 
standards or pooled plasma), which by definition are not in the exact matrix of the test 
sample. While we have made efforts to address some of these challenges in the 
development of a whole-cell zinc biosensor, we sought to develop a related semi-
quantitation method for CFE diagnostics.  
 Here, we present a CFE diagnostic platform capable of semi-quantitatively 
measuring serum zinc levels in an equipment-free fashion. The key innovation is the 
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development of a standardization approach that allows equipment-free quantitation in 
assays consisting of 25-100% human serum. To account for both general matrix effects of 
serum as well as inter-individual donor matrix variation, the standardization scheme is 
designed so that the serum sample to be analyzed is added both to the test reaction and to 
a set of standard reference reactions. Analogous to a litmus test, the color of the test can be 
matched to the colors of the reference reactions so that the user can easily determine the 
sample concentration. The test reliably quantifies clinically relevant zinc concentrations 
and is a significant step towards a low-cost, field-deployable test for zinc deficiency. We 
demonstrate the generalizability of our semi-quantitation method by applying it to a sensor 
that uses an established toehold switch. The developed test is the first CFE assay to provide 
equipment-free biomarker quantification in a complex matrix, and the platform developed 
can be readily expanded to quantify other molecules in cell-free expression reactions. 
4.2 Materials and Methods 
4.2.1 Construction of zinc-responsive circuit 
 Three plasmids were assembled through Gibson assembly: one in which the 
transcription factor ZntR was under the control of a standard T7 promoter, one in which 
PZntA controlled GFP production, and one in which PZntA controlled LacZ production. ZntR 
and PZntA were amplified from a previously described circuit
26. LacZ was amplified from 
BL21(DE3) genomic DNA, and sfGFP was amplified from the plasmid pJL1. All operons 
were cloned into a plasmid containing a ColE1 origin and a kanamycin resistance cassette. 
All plasmids were purified with EZNA midiprep columns and sequence confirmed. 
4.2.2 Construction of knockout strains 
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 Lambda red recombination was used to make all knockout strains100. Two knockout 
strains were constructed: a Lac knockout strain was constructed as previously described76 
to make BL21(DE3) ΔLac, and a dual knockout strain in which ZntR was deleted was also 
constructed: BL21(DE3) ΔLac ΔZntR. For the dual knockout strain, ZntR was first knocked 
out and selected for through antibiotic resistance. Then, the Lac operon was knocked out, 
and blue-white screening was used to determine successful knockouts.  
4.2.3 Preparation of cellular lysate 
 Cellular lysate for all experiments, excluding toehold switch experiments, was 
prepared as previously described63. BL21(DE3) ΔLac ΔZntR cells were grown in 2x YTPG 
medium at 37°C and 180 rpm to an OD of 2.0, which corresponded with the mid-
exponential growth phase. Cells were then centrifuged at 2700 rcf and washed three times 
with S30 buffer. S30 buffer contains 10 mM Tris-acetate (pH 8.2), 14 mM magnesium 
acetate, 60 mM potassium acetate, and 2 mM dithiothreitol (DTT). After the final 
centrifugation, the wet cell mass was determined, and cells were resuspended in 1 mL of 
S30 buffer per 1 g of wet cell mass. The cellular resuspension was divided into 1 mL 
aliquots. Cells were lysed using a Q125 Sonicator (Qsonica, Newton, CT) at a frequency 
of 20 kHz, and at 50% of amplitude. Cells were sonicated on ice with three cycles of 10 
seconds on, 10 seconds off, delivering approximately 180 J, at which point the cells appear 
visibly lysed. An additional 4 mM of dithiothreitol was added to each tube, and the 
sonicated mixture was then centrifuged at 12,000 rcf and 4°C for 10 minutes. The 
supernatant was removed, aliquoted, and stored at -80°C for future use.  
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 Cellular lysate for toehold switch experiments was prepared as previously 
described in Sun, et al115. BL21 Star (DE3) ∆Lac cells were grown in 2x YTP medium at 
37˚C and 220 rpm to an OD of 2.0. Cells were centrifuged at 2700 rcf and washed three 
times with S30A buffer (50mM of Tris, 14 mM magnesium glutamate, 60 mM potassium 
glutamate, 2 mM dithiothreitol, pH corrected to 7.7 with acetic acid). Wet cell mass was 
determined after the third centrifugation step, the cells were resuspended in 1 mL of S30A 
buffer per 1 g of wet cell mass and sonicated using the same method described above, 
though with a sonication output of approximately 400 J. Following the centrifugation of 
the sonicated cellular mixture, the supernatant was removed, divided into 0.5 mL aliquots, 
and incubated at 37˚C and 220 rpm for 80 minutes. After this runoff reaction, the cellular 
lysate was centrifuged at 12,000 rcf and 4˚C for 10 minutes. The supernatant was removed 
and loaded into a 10 kDa MWCO dialysis cassette (Thermo Fisher). Lysate was dialyzed 
in 1L of S30B buffer (14 mM magnesium glutamate, 60 mM potassium glutamate, 1 mM 
dithiothreitol, pH-corrected to 8.2 with Tris) at 4˚C for 3 hours. Dialyzed lysate was 
removed and centrifuged at 12,000 rcf and 4˚C for 10 minutes. The supernatant was 
removed, aliquoted, flash frozen in liquid nitrogen, and stored at -80˚C for future use. 
4.2.4 Cell-free reactions: constitutive expression and zinc-sensing 
 Cell-free reactions for all experiments, excluding toehold switch reactions, were 
run as previously described65. Each cell-free reaction contained 0.85 mM each of GTP, 
UTP, and CTP, in addition to 1.2 mM ATP, 34 μg/mL of folinic acid, 170 μg/mL E. coli 
tRNA mixture, 130 mM potassium glutamate, 10 mM ammonium glutamate, 12 mM 
magnesium glutamate, 2 mM each of the 20 standard amino acids, 0.33 mM nicotine 
adenine dinucleotide (NAD), 0.27 mM coenzyme-A (CoA), 1.5 mM spermidine, 1 mM 
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putrescine, 4 mM sodium oxalate, 33 mM phosphoenol pyruvate (PEP), 27% cell extract, 
and the specified concentration of plasmids. In all reactions producing LacZ, CPRG was 
added to a final concentration of 0.6 mg/mL. All chemicals were purchased from Sigma 
Aldrich. In reactions containing human serum, RNase inhibitor (NEB) was added to a 
concentration of 0.6 U/μL.  
 In all reactions producing GFP, plasmids were added to reactions at a final 
concentration of 20 ng/μL. Plasmid dosage of LacZ and ZntR expression plasmids (pLacZ 
and pZntR) was optimized so that color change would be observable at approximately 60 
minutes. In reactions without serum, pLacZ was added at a concentration of 1.0 ng/μL 
when ZntR was pre-expressed, and at a concentration of 1.5 ng/μL when ZntR was co-
expressed. When ZntR was co-expressed in reactions without serum, pZntR was added to 
reactions at a concentration of 0.5 ng/μL. In all reactions with serum, pLacZ was added at 
a concentration of 15 ng/μL, and pZntR was added at a concentration of 2.5 ng/ul. 
 In experiments in which ZntR was pre-expressed and added to the reaction, ZntR 
was first produced overnight in a cell-free reaction. Reactions were carried out in 1.5 mL 
microcentrifuge tubes, and the reaction volume in each tube was 50 μL. A plasmid 
expressing ZntR was added at 20 ng/μL, and a plasmid expressing a ZntR-GFP fusion 
protein was added at 1 ng/μL. Reactions were incubated at 30°C for 16 hours. Reactions 
were then centrifuged at 12,000 rcf and 4°C for 10 minutes, and the supernatant was 
removed and subsequently used. To measure fluorescence, each reaction was diluted by a 
factor of 10 in DNAse-free ultrapure water. 10 μL was added to a well of a 384 well plate, 
and the fluorescence was measured with a plate reader (Synergy4, BioTek). Excitation and 
emission for sfGFP were 485 and 528 nm, respectively. Fluorescence values were used to 
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account for batch-to-batch variations so that a constant amount of ZntR was added to each 
reaction. Unless otherwise specified, the overnight ZntR reaction was added to fresh 
reactions at a concentration of 1% (+/- variations of less than 0.05% determined through 
fluorescent quantification measurements).  
 CFE reactions were run in 8 μL volumes in 384 well small volume plates (Greiner 
Bio-One), and a clear adhesive film was used to cover the plate and prevent evaporation. 
Fluorescence of GFP was quantified as described above. LacZ activity was monitored by 
measuring absorbance at 580 nm. For time course experiments, plates were incubated at 
37°C, and either fluorescence or absorbance was measured every two minutes. For end-
point experiments, plates were incubated at 37°C, and fluorescence was measured after 22 
hours.  
4.2.5 Cell-free reactions: toehold switches 
 For experiments involving toehold switches, cell-free reactions were run according 
to the protocol described in Sun, et al115. Each reaction contained 1.5 mM of ATP and GTP, 
0.9 mM of CTP and UTP, 0.2mg/mL E. coli tRNA mixture, 0.33 mM of NAD, 0.26 mM 
of CoA, 0.75mM cyclic adenosine monophosphate (cAMP), 0.068 mM of folinic acid, 1 
mM of spermidine, 30mM of 3-phosphoglyceric acid (3-PGA), 50mM of HEPES, 1.5mM 
each of the 20 standard amino acids, 4 mM of magnesium glutamate, 100 mM of potassium 
glutamate, 2% PEG-8000, 33% cell extract, 0.6 mg/mL CPRG, and DNA expression 
plasmids. Toehold switch was expressed from the plasmid pSwitch. Unless otherwise 
specified, the concentration of pSwitch in reactions was 2.5 nM. Trigger RNA was 
produced from 40 ng/μL linear DNA template in an in vitro transcription reaction using T7 
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RNA Polymerase (NEB), following the manufacturer’s protocol. Synthesized RNA was 
treated with DNase to remove the DNA template and then purified using a Zymo RNA 
Clean and Concentrator kit (R1014), according to the manufacturer’s protocol. The 
concentration of trigger RNA added varied across experiments. Time course reactions were 
run as described above.  
4.2.6 Determination of best-fit reactions and predictive standard reactions 
 In determining which standard reference reaction best fit each zinc concentration, 
sum of squared error (SSE) minimization was used. The difference between each standard 
and test reaction was calculated at all time points between 30 and 90 minutes. The SSE 
was calculated over this time frame, and the standard reaction that had the lowest SSE was 
determined to be the best-fit reaction and thus the optimal regulator for that experimental 
run. When choosing what regulator concentration best predicts each potential biomarker 
concentration, we determined the overall optimal regulator concentration as the one closest 
to the average of the optimal matching regulator concentration across three runs. 
4.2.7 Quantitative Error Metric Calculations 
 We defined a quantification error metric (QEM) to compare the absorbance 
readings of the test and standard reactions that should predict the test reaction. We first 
calculated the difference between prediction and absorbance readings at each time point.. 
 Δ𝐴(𝑖, 𝑗) =  |𝐴580,𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑(𝑖) −  𝐴580,𝑎𝑐𝑡𝑢𝑎𝑙(𝑗)| (1) 
𝑖 = index of zinc prediction 
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𝑗 = index of zinc test evaluated 
 Then, we calculated the normalized sum of squared error for the correct prediction 
readings for each zinc concentration. We defined this as the QEM of the correct predictions 
(QEMcorrect). Ideally, the QEMcorrect should be zero to indicate identical absorbance curves 









𝑛 = number of zinc concentrations evaluated 
𝑖 = index of zinc concentration evaluated 
 We next calculated the normalized sum of squared error for the closest incorrect 
predictions and defined this as the QEMincorrect. Ideally, the QEMincorrect should be very high 
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𝑛 = number of zinc concentrations evaluated 
𝑖 = index of zinc concentration evaluated 
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 In all evaluation of quantification error, we set a threshold of 0.0484, which is 0.222. 
Across all experiments, the average maximum A580 value was approximately 2.2, so 0.22 
corresponds with one-tenth of the spectrum. Values below the threshold indicate 
indistinguishable differences, and values above the threshold indicate distinguishable 
differences.  
4.2.8 Preparation of human serum 
 Pooled human serum was purchased from Corning. Chelex 100 (BioRad) was used 
to deplete zinc from the serum. 1 g of resin was added to 100 mL of serum, and serum was 
stirred for 2 hours. Resin was removed from serum through filtration.  
 In single donor experiments, blood was collected from donors as approved in IRB 
protocol number H17489. Venous blood was collected in 6 mL BD Vacutainer collection 
tubes for trace element testing, and tubes were left on ice for 30 minutes to clot. Blood was 
then transferred to a 50 mL conical tube and centrifuged at 2700 rcf, 4°C for 30 minutes. 
The serum was removed and either immediately frozen or treated with Chelex-100 resin. 
80 mg of resin was added to 8 mL of serum, and the mixture was vigorously stirred for 2 
hours. Resin was isolated from the samples through centrifugation, and serum was syringe 
filtered. All serum samples were aliquoted to minimize freeze-thaw cycles and stored at -
20°C. 
4.2.9 Zinc measurements 
 Zinc concentration of pooled serum was analyzed using an X-Ray Fluorescence 
spectrometer. 2 μL of serum was spiked with 1 ppm of a gallium internal standard, pipetted 
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onto a quartz disc, and atomic fluorescence emission spectra were collected. Zinc 
concentration in individual donor serum samples was measured at the University of 
Georgia Laboratory for Environmental Analysis. Samples were digested with concentrated 
acid and analyzed on an ICP-MS according to EPA method 3052.  
4.2.10 Spectra analysis 
 To analyze the spectrum of chlorophenol red and reaction intermediates, a large 
batch of concentrated chlorophenol red was made by adding CPRG to a small amount of 
extract made from standard BL21(DE3) cells (which have high baseline LacZ activity). 
The spectrum of CPR was analyzed to ensure that all CPRG reacted to CPR by screening 
for absence of a detectable peak at 410 nm. Different combinations of CPRG and CPR 
were then added to solutions containing 27% bacterial cell extract (made from BL21(DE3) 
ΔLac cells), with or without serum. The final concentration of dye in each solution analyzed 
was 1.02 M, which corresponds with addition of 0.6 mg/mL of CPRG. 
 When adding small molecules to the reaction, 10x stocks of each molecule were 
made. Penicillin, dicloxacillin, and naproxen were dissolved in water, ibuprofen was 
dissolved in ethanol, and sulfisoxazole was dissolved in chloroform. 3 L of each stock 
was added to PCR tubes, and tubes were left open in a fume hood overnight so that solvents 
could evaporate. A 30 L solution containing the specified amount of dye, protein extract, 
and serum was used to re-dissolve the small molecule. Concentrations reported are the final 
concentration of small molecule in the analyzed solutions.  
 The spectra of all solutions reported were measured in triplicate with a Nanodrop 
2000. When analyzing reaction intermediates, spectrum height was normalized to a peak 
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at 280 nm. When further analyzing the peak corresponding with CPR, each spectrum was 
first height-normalized so that the maximum of the peak corresponding with chlorophenol 
red was the same for all spectra. Then, the wavelengths that correspond with 4 different 
absorbance intensities were determined and subtracted from the values of the control 
spectrum. The four differences were averaged to compute the overall wavelength shift. 
Reported averages are the average of the overall wavelength shift of the three initial 
replicates.  
4.2.11 Color imaging and processing 
 All pictures were taken with a Panasonic Lumix camera in a light-controlled setting. 
All pictures in figures showing color results are of 8 L reactions in 384 well plates. The 
centers of selected reaction wells were cropped using Adobe Photoshop and combined to 
make color arrays. A brightness filter was applied to photos to make them better resemble 
actual appearance.  
4.2.12 Lyophilization 
 30 L reactions were prepared in PCR tubes and flash frozen in liquid nitrogen. 
Frozen samples were removed from liquid nitrogen and added to a Labconco Fast-freeze 
flask that contained a small amount of liquid nitrogen. Care was taken to transfer samples 
quickly and keep samples cold throughout the transfer process. Flasks were connected to a 
LabConco benchtop freeze-drier and lyophilized at -50°C and 0.05 mbar for 3 hours. 




4.3.1 Development of a cell-free zinc detection system 
 In developing a cell-free quantification method, we chose to use zinc as the model 
analyte because of its global health relevance21 and our group’s previous experience in 
developing whole-cell zinc biosensors25,26,79. To begin, we tested whether zinc-responsive 
elements could properly control output in a CFE reaction. We constitutively expressed the 
zinc-responsive activator ZntR, and used this transcription factor to control GFP expression 
from ZntR’s cognate promoter PzntA (Figure 24A). The system showed dose-dependent zinc 
response between 0 and 8 µM (Figure 24B), demonstrating that zinc can be detected in a 
cell-free system. Notably, the system also showed a dramatic decrease in protein 
production at higher zinc concentrations, which can likely be attributed to decreased 
expression from native E. coli σ70 promoters at high zinc concentrations (Figure 24C).  
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Figure 24: Cell-free expression systems respond to added zinc.  
(A) Schematic of a zinc-responsive circuit used to control GFP production. ZntR is 
expressed from a T7 promoter, and GFP is expressed from the ZntR-activated 
promoter PzntA. (B) Fluorescent output in response to zinc. (C) Effect of zinc on 
expression from constitutive promoters. Increasing amounts of zinc slightly decrease 
expression from T7 promoters and substantially decrease expression from σ70 
promoters. GFP was used to measure protein expression. Error bars represent 
standard deviation. 
 To better enable equipment-free testing, we replaced the GFP reporter with beta-
galactosidase (LacZ) to create a colorimetric output (Figure 25Figure 24A), using a 
bacterial extract with no LacZ or ZntR background activity. LacZ cleaves the yellow 
substrate chlorophenol red-β-D-galactopyranoside (CPRG) to the purple product 
chlorophenol red (CPR) and has previously been used in the development of low-resource 
diagnostic tools15. Colorimetric output can be quantified by measuring absorbance at 580 
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nm or assessed qualitatively by looking at reaction color. Different ratios of CPR to CPRG 
create a large spectrum of colors (Figure 25B) that directly correspond with absorbance 
readings.  
 Using this system, we engineered a colorimetric response to zinc concentrations 
(Figure 25C, Figure 25D). At early time points, there is no detectable LacZ activity, and 
all reactions look yellow. Between 50 and 80 minutes, the test clearly differentiates 
between zinc concentrations, with better differentiation of high zinc concentrations at 
earlier times and better differentiation of lower zinc concentrations at later times. At late 
reaction time points (90 minutes), almost all of the reactions have gone to completion (all 
tests with zinc concentrations over 2 μM look purple). As reactions proceed from yellow 




Figure 25: Colorimetric response to added zinc in CFE reactions.  
(A) Schematic of a zinc-responsive circuit used to control LacZ expression. (B) 
Pictures of visible colors from reactions corresponding with different absorbance 
measurements. The lowest A580 readings correspond with yellow reactions, and as the 
A580 increases, the reaction color turns different shades of orange, red, and purple. 
(C) Quantitative colorimetric response to added zinc. At early time points, there is no 
detectable absorbance of the purple substrate CPR at tested [Zn2+]. As the reactions 
proceed, they produce CPR at different rates based on the concentration of Zn2+ in 
the reaction, with maximal differences visible between 60 and 70 minutes. Ideal assay 
readout times would span a wide range of absorbances across as much of the [Zn2+] 
range as possible. (D) Qualitative colorimetric response to added zinc. Reactions that 
were measured quantitatively in (C) were imaged at different time points. Between 
60 and 80 minutes there is a clear color gradient based on zinc concentration.  
 
 
To tune reaction timing for detection purposes, we modulated the concentration of 
reporter plasmid in the reaction. As expected, higher concentrations of the reporter plasmid 
(pLacZ) decrease the incubation time required for visible color, though they also decrease 
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the time frame in which a dose-dependent zinc response is detectable (Figure 26). Thus, 




Figure 26: Effect of reporter plasmid concentration on ability to distinguish between 
different zinc concentrations.  
Zinc concentrations were considered indistinguishable if the difference in A580 
readings between two concentrations was less than 0.22. Times highlighted in red 
indicate that the absorbance difference between the two concentrations on the y-axis 
is above this threshold and thus the user can visualize colorimetric differences 
between the two concentrations. 
 Direct addition of the regulator ZntR to reactions (rather than simultaneous 
expression in the sensing reaction) could potentially improve sensor performance by 
simplifying the genetic circuitry in the reaction and reducing the number of added 
components. We showed that cell-free systems can detect zinc when the regulator ZntR is 
pre-expressed and subsequently added to the reaction at a fixed amount rather than being 
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co-expressed in the reaction. We overexpressed ZntR in an overnight CFE reaction and 
then added a small amount to a fresh sensing reaction. These reactions with pre-expressed 
ZntR show a reproducible zinc response (Figure 27) similar to the response when ZntR is 
simultaneously expressed in the reaction (Figure 25C) but show slight differences in range 
of detectable zinc. Though both tests show nearly linear changes in color output between 
0 and 4 µM zinc, tests with co-expressed ZntR show further changes between 4 and 8 µM 
zinc, while tests with pre-expressed and added ZntR showed nearly identical output across 
this concentration range.  
 
Figure 27: Direct addition of ZntR protein mediates a response to added zinc.  
(A) Validation of ZntR protein addition to mediate CFE reactions. ZntR was 
expressed in 4 different batches, on different days and in different batches of cellular 
extract. When added to the reaction, each batch of ZntR mediated a nearly identical 
response to different concentrations of zinc. (B) Quantitative colorimetric response to 
zinc when ZntR is pre-expressed and added to the CFE reaction. Reactions controlled 
by pre-expressed ZntR respond similarly to reactions controlled by ZntR that is 
simultaneously expressed in the sensing reaction. 
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  The developed test is compatible with field-friendly technologies. The CFE test 
with co-expressed ZntR was lyophilized and rehydrated in water with a range of zinc 
concentrations. Though the response is slightly slower than fresh reactions, the system 
shows a zinc response similar to that of reactions run without lyophilization (Figure 28), 
which demonstrates the potential for our zinc test to be field deployable. 
 
Figure 28: Quantitative colorimetric response to zinc of lyophilized reactions that 
were rehydrated in different zinc concentrations.  
Zinc response is similar to that of fresh reactions. The incubation time required to 
observe color differences is slightly longer, but at intermediate and later time points 
(60 – 90 minutes), the color production varies between 0 and 8 μM Zn2+. 
4.3.2 CFE systems sense and respond to zinc in human serum 
 Since many biomarkers (including zinc) are measured in human serum or plasma, 
we next tested whether CFE systems could work in high serum concentrations. Previously 
developed CFE diagnostics amplify nucleic acids from a 10% serum matrix, but because 
of upstream processing steps, the final CFE reaction consists of less than 1% serum16. 
Similarly, minimal-equipment CRISPR-based diagnostics have only been shown to work 
in a 2% serum matrix75. Since an ideal in-field test would require minimal sample 
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processing and dilutions, we aimed to run the test in the highest possible concentration of 
serum.  
 We first showed that CFE reactions produce protein in a 25% serum matrix with 
addition of RNAse Inhibitor (Figure 29A). Because of the volume of necessary reaction 
components, 25% serum is the highest concentration that we could reasonably test using 
freshly assembled reactions. Though serum matrix effects reduce protein expression from 
both T7 and native E. coli promoters (Figure 29B), the observed expression levels still 
support the viability of running reactions in up to 25% serum.  
 
Figure 29: Protein production in high concentration of serum. 
(A) Effect of RNAse inhibitor on CFE reactions in 25% serum. Inhibition of RNAse 
activity is necessary for protein expression in serum. In the absence of RNAse 
Inhibitor (RNAseI), reactions produce no detectable protein, and increased amounts 
of RNAseI enable expression. (B) Protein expression in reactions run in serum. The 
protein sfGFP was expressed from either a T7 or σ70 promoter. CFE reactions 
produce protein from both T7 and σ70 promoters in a matrix of up to 25% serum, 
which was the highest that could be tested in freshly assembled reactions. 
 To test whether the system could detect zinc in this matrix, we used Chelex 100 
resin to remove zinc from pooled human serum, and confirmed that the concentration was 
reduced to 2.5 µM with X-Ray Fluorescence. We then added a range of zinc concentrations 
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to the treated serum. Reactions run in serum respond to a similar concentration range of 
zinc as reactions run in water, but reactions in serum have lower protein production at all 
zinc concentrations (Figure 30A). Because we wanted the colorimetric test to produce 
visible color quickly, we accounted for observed changes in overall protein production by 
adding a higher concentration of the LacZ reporter plasmid to reactions that contained 
serum (see Methods). Reactions run in 25% serum show colorimetric differences based on 
zinc concentration (Figure 30B) 
 Since an ideal low-resource test would not require any dilutions, we tested the 
function of lyophilized reactions that were reconstituted in pure serum. Reactions 
rehydrated in pure serum produce protein from both T7 and native E. coli promoters 
(Figure 30C) and regulate a response to a large range of zinc concentrations (Figure 30D). 
Reactions run in 100% serum produce differential color across the entire range of zinc 
concentrations tested (between 2.5 and 22.5 µM zinc), suggesting that not only is simplified 
testing with undiluted samples possible, but it may in fact provide a wider dynamic range 
for measurement.  
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Figure 30: Zinc response in high concentrations of serum.  
(A) Fluorescent response to zinc in 25% human serum. (B) Quantitative colorimetric 
response to zinc in 25% serum when ZntR is co-expressed in the CFE reaction. A 
higher concentration of LacZ plasmid was used so that color differences are visible 
between 60 and 80 minutes. (C) Protein expression in reactions run in 100% serum. 
CFE reactions expressing sfGFP from either a T7 or σ70 promoter were lyophilized 
and rehydrated in either water or serum. CFE reactions produce protein from both 
T7 and σ70 promoters in 100% serum, but expression is substantially lower than in 
reactions rehydrated with water. (D) Quantitative colorimetric response to zinc in 
lyophilized reactions rehydrated in different amounts of zinc. Color differences are 
apparent after 60 minutes, and the color output varies across the entire range of zinc 
tested (2 – 22 μM Zn2+).  
4.3.3 Development of parallelized calibration method 
 To make these measurements of serum field-friendly and equipment-free, we then 
developed a standardization method so that the color of the test reaction can be matched to 
an array of standard reactions run in the exact same sample matrix as the test reaction 
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(Figure 31). The standard reactions have saturated zinc concentrations and varying 
amounts of transcriptional regulator so that regulator concentration, rather than zinc 
concentration, controls colorimetric output. Importantly, the matrix effects of serum on 
CFE machinery will be identical in both the sample and the standards. Before testing this 
in the matrix of human serum, we first validated this approach in reactions that did not 
contain serum.  
 
Figure 31: Matrix-specific quantification scheme for test standardization.  
An array of standard reactions has saturated zinc concentrations and varied 
regulator concentrations. The test reaction will have a set regulator concentration and 
no added zinc. The sample to be analyzed will be added to both the standard and test 
reactions so that all reactions run in the same sample matrix. After a set incubation 
time, the color of the test reaction can be matched to the color of the standard 
reactions to determine zinc concentration in the test reaction. 
 For this approach to be valid, the colorimetric response must saturate and be 
identical over a range of zinc concentrations to account for the zinc in the sample being 
added to the already-saturated standard reactions. In this range of zinc concentrations, 
reaction output will only depend on regulator concentration. Early experiments with 
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fluorescent reporters showed that the system’s zinc response is at a plateau by 8 µM and 
has decreased expression by 15 µM (Figure 24B). When we characterized this behavior at 
a finer resolution and with a colorimetric reporter, we found the output to be identical when 
reactions were run in zinc concentrations between 7 and 11 µM (Figure 32A). So, if 7 µM 
zinc is in each standard reaction and each raw sample has no more than 4 µM, then the 
final standard reactions will have between 7 and 11 µM of zinc, and thus have constant 
colored output. This enables the test to differentiate raw zinc concentrations between 0 and 
4 µM, corresponding to a clinically relevant serum zinc range of 0 to 16 µM if reactions 




Figure 32: Development of matrix-specific quantification scheme for test 
standardization.  
(A) Colorimetric response is identical across a range of zinc concentrations in 
reactions run without serum. Reactions with different regulator concentrations were 
run in a range of zinc concentrations. In all tests, colorimetric output is the same 
across the range of 7 to 11 μM zinc. (B) Selected time-course readings of test and 
standard reactions without serum. (C) Relationship between zinc concentration in the 
test reaction and the ZntR concentration in the standard reaction that most closely 
matches the test reaction. 
 We then determined what regulator concentrations in standard reactions would 
correspond to different zinc concentrations in test samples (all without serum). We ran a 
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large array of standard reactions with 8 µM zinc and a range of regulator concentrations in 
parallel with test reactions that had set regulator concentration and a range of zinc 
concentrations. We determined which standard reaction most closely matched each test 
reaction (assessed by sum of squares error across measurements at all time points). For 
each concentration of zinc tested, a standard reaction showed nearly identical colorimetric 
output (Figure 32B). The concentration of zinc in test reactions is highly correlated with 
the regulator concentration in the standard reactions that most closely matches the test 
output (Figure 32C), and correlations were consistent across experiments run on different 
days and in different batches of cell extract. Of the regulator levels that best matched each 
target zinc concentration for the three different runs, we used the regulator level closest to 
the average for the optimal set of regulator concentrations to correspond to each zinc 
concentration.  
4.3.4 Parallel calibration reliably quantifies zinc concentrations 
 We assessed the accuracy of the test by comparing the absorbance of test reactions 
with the absorbance of predictive standard reactions (with the previously-identified 
regulator concentrations). When tests were evaluated at 70 minutes, all tests were 
appropriately classified into 1 μM raw concentration bins (Figure 33A). 
 To assess test prediction accuracy and specificity for all possible measured values 
across all time points, we defined a quantification error metric (QEM). The QEM captures 
the differences in absorbance, across all zinc levels, between the actual reaction for a given 
zinc level and a given predictive standard reaction (Methods). Ideally, the QEM of the 
correct predictions should be zero, and the QEM of the incorrect predictions should be 
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high. We set a QEM threshold that corresponds with the ability to differentiate between 
one-tenth increments of the color spectrum (Figure 25B). In all serum samples, the QEM 
of the correct predictions is substantially lower than the set threshold, and the QEM of the 
closest incorrect predictions is substantially higher than the threshold (Figure 33B), 
indicating unambiguous interpretability of test results. Tests can also be interpreted without 
equipment across the time course of the test, by comparing the color of the test reactions 
to the color of the predictive standard reactions (Figure 33C). 
 
Figure 33: Quantification approach provides high prediction accuracy.  
(A) Quantification of zinc concentrations for all four test runs, at 70 minutes. Runs 1-
3 were used in initial calibration, and Run 4 was only used in test validation. Symbols 
falling inside the horizontal bars that correspond with the binned prediction ranges 
for each y-axis level indicate accurate predictions. (B) Error quantification of all test 
runs evaluate via the Quantification Error Metric (QEM). Low QEM for correct 
predictions and high QEM for incorrect predictions indicates unambiguously 
interpretable test results for a given time. (C) Visualization of reactions from Run 4. 
Pictures show test and predictive standard reactions at different time points. 
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 We next evaluated how well the test predicts zinc concentrations when subject to 
variations in reaction conditions. Though optimal standards were chosen by correlations 
determined at 37°C, the test accurately quantifies zinc when run at both 34°C and 40°C. 
The QEM of the correct predictions is higher than when run at 37°C, but the QEM 
thresholds are still met for at least 20 minute intervals, and sometimes much longer, during 
the testing time, indicating that the classification is sufficiently good (Figure 34).  
 
Figure 34: Quantification error for tests run in nonideal reaction conditions.  
The test accurately classifies zinc when run at varied temperatures and following 
lyophilization, as indicated by correct predictions falling below the threshold and 
incorrect predictions falling above the threshold.  
 The test can also predict zinc concentrations following lyophilization. Test 
reactions were assembled with no added zinc, and standard reactions were assembled with 
8 μM added zinc. All reactions were lyophilized and then rehydrated in water (standard 
reactions) or in different zinc concentrations (test reactions). Rehydrated tests accurately 
predicted zinc concentration (Figure 34). 
 Because of the potential advantages of using pre-expressed protein to mediate test 
response, we used an identical calibration approach for test set-ups in which ZntR is 
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directly added. Tests can also accurately predict zinc concentrations when the regulator 
ZntR is pre-expressed and then added to the reaction (Figure 35). 
 
Figure 35: Validation of zinc quantification with direct protein addition.  
(A) When ZntR protein is added directly to the reaction, the zinc response saturates. 
In all tests, colorimetric output is the same across the range of 7 to 11 μM zinc. This 
enables the test to differentiate raw zinc concentrations between 0 and 4 µM. (B) 
Selected time course readings of test and standard reactions run with direct protein 
addition. A large array of standard reactions with 8 µM zinc and a range of regulator 
concentrations was run in parallel with test reactions that had set regulator 
concentration and a range of zinc concentrations. For each concentration of zinc 
tested, a standard reaction showed nearly identical colorimetric output to a test 
reaction. (C) Relationship between zinc concentration in the test reaction and the 
ZntR concentration in the standard reaction that most closely matches the test 
reaction for tests run with direct protein addition. Correlations are consistent across 
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experiments run on different days and in different batches of cell extract. We 
determined the optimal set of regulator concentrations to correspond to each zinc 
concentration by choosing the regulator concentration closest to the average 
regulator concentration across three runs. (D) Quantification of zinc concentrations 
in reactions with direct protein addition for all four test runs, at 70 minutes. Symbols 
falling inside the horizontal bars that correspond with the binned prediction ranges 
for each y-axis level indicate accurate predictions. (E) Quantification error metrics 
for tests run with direct protein addition. In all runs, the QEM of the correct 
predictions is far below the threshold, and the QEM of the incorrect predictions is 
above the threshold between 70 and 90 minutes.  
4.3.5 Addition of small molecules enables equipment-free quantitation in serum 
 Ideally, for an equipment-free test, users could easily match the color of the test 
reaction to the color of standard reference reactions, similarly to how one reads a litmus 
test. The diverse array of colors that correspond with different levels of CPRG cleavage 
into CPR (Figure 25B) readily enables an easy interpretation of zinc levels. However, when 
the test is run in serum, the distinct colored intermediates (orange and red) are eliminated, 
and all intermediate reactions states are varying, difficult-to-interpret degrees of yellow 
and purple (Figure 36A). While this has minimal effect when quantifying test output via 
absorbance, lack of distinct intermediates makes quantitation by eye much more 
challenging. 
 To probe what could cause this color change, we looked at the absorption spectra 
of reactions that contained different ratios of CPR and CPRG, with or without 25% serum 
(Figure 36B). All reactions showed only two distinct peaks: one at 410 nm that is larger 
early in the reaction and another around 580 nm that grows as the reaction proceeds. In the 
presence of serum, the first peak is smaller, and, more prominently, the second peak shifts 
approximately 10 nm which greatly affects the perceived color. 
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Figure 36: Serum alters the color of reactions, making test interpretation more 
difficult. 
(A) Reactions run in serum appear different from reactions run in the absence of 
serum. Reactions with complete conversion of CPRG to CPR appear more purple in 
a 25% serum matrix. More importantly, in 25% serum the colored orange and red 
reaction intermediates initially observed are no longer visible. (B) Absorption spectra 
for incomplete reactions of CPRG cleavage to CPR in water and serum. Spectra 
correspond with the numbered reactions in (A). In both water and serum, only two 
peaks are visible. The peak at 400 nm decreases as the reaction proceeds, and the peak 
near 580 nm grows. There is a shift in the 580 nm peak of about 10 nm when reactions 
are run in serum.  
Since dyes with similar structures to CPR are known to interact with serum albumin and to 
change color in the presence of albumin116,117, we hypothesized that the color change 
observed could be caused by albumin interaction with CPR. We tested the effect of human 
serum albumin (HSA) on the spectrum of chlorophenol red and observed a nearly identical 
spectrum shift (Figure 37A) to that seen in serum. We used E. coli protein extract at the 
same overall protein concentration as serum to test whether this effect could be due to 
nonspecific protein interaction. This protein mixture caused a slight shift in the visible 
spectrum, but less than 30 percent of the shift that HSA caused, further supporting that 
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CPR’s interaction with albumin, rather than with protein in general, is the primary cause 
of the color change.  
 
Figure 37: Addition of small molecules that interact with serum albumin reverses the 
spectral shift and restores distinct colored intermediates 
(A) Human serum albumin (HSA) uniquely replicates the spectrum shift caused by 
serum. Data shown is the average spectrum shift from three biological replicates, and 
error bars indicate standard deviations. (B) Addition of small molecules that bind 
albumin reverses the spectrum shift. (C) Addition of naproxen restores distinct color 
intermediates. Naproxen added at 5 mM made completed reactions appear less 
purple but did not fully restore the orange and red colored intermediates. Naproxen 
added at 40 mM made the reaction colors visually indistinguishable from reactions 
run without serum. 
 Albumin binds a wide variety of compounds118, and we explored whether we could 
reverse the color change by adding a molecule to displace CPR from albumin. Albumin 
has two primary binding pockets (referred to as Site I and Site II), and since molecules with 
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structures similar to CPR are known to bind to Site I, we first tested the effect of adding 
other known Site I binders: penicillin, dicloxacillin, and sulfisoxazole. All three slightly 
shifted the spectrum at high concentrations, and dicloxacillin had the strongest effect. We 
also explored the effect of adding Site II binders: naproxen and ibuprofen. Both of these 
dramatically shifted the spectrum, nearly restoring reaction color to its appearance without 
added serum (Figure 37B, Figure 37C) 
 We next tested whether CFE reactions were compatible with addition of these 
compounds at concentrations that would prevent spectral shifts. When reactions without 
serum were run in naproxen, ibuprofen, and dicloxacillin (the three most effective color-
reversers), all small molecules (perhaps unexpectedly) decreased or eliminated expression 
when added at 5 mM (Figure 38), though reactions in serum better tolerated higher 
concentrations of added drug. However, even in reactions with serum, all drugs still 
decreased expression when added at a concentration of 5 mM, less than what is required to 
reverse the color change, and at concentrations of 10 mM, all drugs completely inhibited 
reaction progression (Figure 38). While these limitations preclude running reactions in the 
presence of the small molecules, these molecules can be added at the time of sample 
reading to ensure proper visible color, and if added in combination with LacZ inhibitors, 
they could even quench the CFE reaction as well, enabling long-term test storage and 
potential later test analysis. 
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Figure 38: Effect of small molecules on output from CFE reactions.  
The small molecules that had the greatest spectrum shift were added to CFE reactions 
with or without 25% serum. In water, all molecules decreased or eliminated 
expression when added at 5 mM. Notably, when 5 and 10 mM ibuprofen was added, 
reactions became cloudy, which likely caused the higher observed absorbance 
readings at early time points. In 25% serum, reactions ran more successfully with 
intermediate concentrations of added small molecules, but reactions still could not 
run in 10 mM of any added compound.  
4.3.6 Tests reliably quantify zinc in the matrix of single-donor human serum 
 One of the main advantages of this test design is its ability to account for and 
overcome the matrix effects associated with serum samples compared to reactions not in a 
serum matrix. However, the design must also be robust to the matrix effects associated 
with variation in serum constituents across individual patient samples. To determine 
whether our diagnostic meets this criterion, we tested its ability to predict zinc levels in 
human serum taken from individual donors.  
 Blood samples were collected from four different donors, and serum was isolated 
from whole blood through centrifugation. Because the samples obtained had healthy levels 
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of serum zinc, we needed to first remove zinc from the sample to allow for tuning and 
selection of ZntR concentrations for standards. As in our initial serum testing, we depleted 
zinc from each sample, measured the zinc concentration of the treated serum (Figure 39A), 
and then supplemented zinc to create serum with a range of zinc concentrations.  
 To establish a complete proof-of-principle test, correct ZntR concentrations for test 
reactions in 25% serum matrix were then identified for our prediction method, as described 
above. Because of the better overall test performance and greater consistency when ZntR 
was expressed simultaneously in reactions, we only explored using this reaction scheme, 
and we used a reporter plasmid concentration such that the test would be interpretable 
between 50 and 60 minutes. We first identified that a set of standard reactions behaved 
identically across a raw concentration range of 8 to 16 μM added zinc (which corresponds 
to a serum zinc range of 32 to 64 μM zinc for reactions run in a 1:4 sample dilution) (Figure 
39B). Then, to determine the optimal set of regulators to predict each zinc concentration, a 
set of test and standard reactions were run in pooled serum taken from the first three donors. 
From these test runs, we determined the optimal set of regulators to predict zinc 
concentration in the matrix of 25% human serum (Figure 39C). Though the relationship 
between regulator levels in prediction reactions and zinc concentrations in test reactions 
varied across test runs at high zinc concentrations, the optimal set of standards still 
successfully discriminated between zinc levels in pooled samples (Figure 39D). 
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Figure 39: Development of CFE assay to assess serum zinc concentrations.  
(A) Zinc concentrations in individual donor serum before and after treatment with 
Chelex-100 resin. Serum from donors 1-3 was used for test calibration and evaluation, 
and serum from donor 4 was used only in test validation, indicated by the asterisk. 
(B) Colorimetric response is identical across a range of zinc concentrations. Reactions 
with different regulator concentrations were run in a range of zinc concentrations. In 
all tests run in 25% serum, colorimetric output was the same across the raw range of 
8 to 16 μM zinc, which corresponds with 32 to 64 μM zinc in the serum sample. (C) 
Scatter plot of zinc concentrations and the corresponding regulator concentrations 
that yield similar output in 25% human serum. Runs 1-3 represent experiments 
performed separately and in different batches of cell extract. Zinc values reported are 
the equivalent of those in the pure serum samples, translated from the raw values 
measured by the reactions. (D) QEM of Runs 1-3, using the optimum standards 
predicted from the correlation shown in (B).  
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 We next evaluated the ability of the overall test to quantify serum zinc levels in 
samples from individual donors, using concentration bins with a width of 4 µM. The test 
accurately predicted zinc concentration for all samples, including serum from Donor 4, 
which notably was not used during the assay calibration described above. We added 
different amounts of zinc to the different zinc-depleted donor samples to probe how well 
the test quantified zinc concentrations on the outer edges of the bins. The test accurately 
classified all zinc concentrations between 0 and 20 µM (Figure 40A). Though the test 
inaccurately classified some higher zinc concentrations, the range of accurate predictions 
covers all physiologically relevant serum zinc concentrations. We further evaluated test 
accuracy and sensitivity as previously described. For each donor, the QEM of the correct 
prediction was far below the set threshold, and the QEM of the incorrect prediction was 
above the threshold (Figure 40B). The test was also robust to temperature variations and 
lyophilization (Figure 40C).  
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Figure 40: Accurate quantification of zinc in human serum.  
(A) Quantification of serum zinc concentrations for all four donors tested, evaluated 
at 56 minutes. (B) Error quantification of all individual donor samples. (C) Error 
quantification in non-ideal reaction conditions with serum from Donor 4. 
 Finally, we demonstrated the equipment-free potential of our test. A set of test and 
standard reactions was run in serum from Donor 4 with different concentrations of added 
zinc (for test reactions) and a saturated zinc concentration (for standard reference 
reactions). After 50 minutes, either 40 mM naproxen or an equivalent volume of water 
were added to reactions. Test reactions clearly correspond with the appropriate binned 
standard reactions (Figure 41), and tests with added naproxen are more easily interpreted 
because of the distinct color intermediates.  
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Figure 41: Equipment free test interpretation in 25% serum.  
Tests were run for 50 minutes, and then visualized either with or without 40 mM 
naproxen addition. With added naproxen, the color of test reactions matches the color 
of the appropriate standard reference reaction. 
4.3.7 Approach to semi-quantitation is generalizable to toehold sensors 
 To demonstrate the generalizability of our quantification approach, we applied the 
same framework to quantification of DNA with an established toehold switch, a sensing 
modality used in recently developed infectious disease diagnostics. Using previously 
characterized switch and trigger sequences15, we expressed a toehold switch in CFE 
reactions, and added the corresponding trigger RNA (Figure 42A). We designed the system 
such that test reactions have a set amount of toehold switch (the response regulator) and 
variable amounts of toehold trigger (the analyte), and standard reference reactions have 
saturated levels of toehold trigger and variable amounts of the toehold switch. For each 
trigger concentration tested, a standard reaction shows a nearly identical colorimetric 
output (Figure 42B), and the relationship between trigger concentration in the test reactions 
and switch concentration in standard reactions is consistent across experiments (Figure 
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42C). From these data, we determined the optimal set of switch concentrations that match 
each trigger concentration. 
 When we evaluated each experiment with the optimal set of standards, the test 
accurately quantified trigger concentration for all trigger concentrations tested (Figure 
42D). QEM quantification (Figure 42E) shows nearly ideal test behavior across time 
points, and the colors of the test reactions accurately match the color of the correct 
corresponding standard reactions (Figure 42F). 
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Figure 42: Quantification approach is generalizable to toehold switches.  
(A) Schematic of toehold switch used to control LacZ production. Trigger RNA 
unfolds the toehold switch and enables LacZ translation. Increasing amounts of 
trigger RNA correspond with increased LacZ translation. (B) Selected time-course 
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readings of test and standard reactions for a toehold sensor. A large array of standard 
reactions with saturated trigger RNA concentrations and a range of switch 
concentrations was run in parallel with test reactions that had set switch 
concentration and a range of trigger concentrations. For each concentration of trigger 
tested, a standard reaction showed nearly identical colorimetric output. (C) 
Relationship between trigger concentration in the test reaction and the corresponding 
toehold switch concentration in the calibration reaction that most closely matches the 
test reaction. (D) Test quantification of trigger concentrations, evaluated at 40 
minutes. Purified RNA was added to each sample at different, known concentrations. 
Symbols falling inside the horizontal bars that correspond with the binned prediction 
ranges for each y-axis level indicate that the CFE test accurately quantified DNA in 
the sample. (E) Quantification error for toehold sensing. (F) Visualization of test and 
standard reactions, evaluated at 40 minutes. The color of test reactions matches the 
color of the appropriate standard reference reaction. 
4.4 Discussion 
 In this work, we develop a cell-free diagnostic platform capable of measuring a 
small analyte in a complex matrix. The output from our portable system can be monitored 
in a semi-quantitative manner with the naked eye. Importantly, rather than using common 
inducers (e.g., IPTG) for proof-of-principle development, we instead focused on a 
clinically-relevant target and developed an assay with imminent translational potential. We 
demonstrate that our approach can reliably quantify zinc in human serum at clinically 
relevant levels, and that it can be broadly applied to quantification of other molecules in 
complex matrices. By adding the same sample to both standard and test reactions, we 
account for all of the matrix effects introduced by serum samples and individual variation 
across samples. Our approach significantly expands the scope of CFE diagnostic tools to 
assessment of medical conditions that need more than just binary identification of presence 
or absence of a biomarker, and thus in turn significantly expands the potential impact of 
CFE diagnostics in biomedicine and global health.  
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 To date, CFE diagnostics have been limited to infectious diseases and other 
conditions with nucleic acid biomarkers. In these cases, it is merely the presence or absence 
of the marker that matters for diagnosis, and so the important analytical figure of merit is 
sensitivity. However, many more medical conditions have biomarkers where binary 
identification of presence or absence is insufficient for diagnosis. In these cases, a usable 
diagnostic requires some degree of quantification, and relevant analytical considerations 
include accuracy, detection range of the measurement, resolution of the quantification, and 
robustness of the quantification to variations in the sample matrix.  
 In this work we specifically address the impacts of the sample matrix on accuracy 
and robustness of quantification with an approach that is effective even in resource-poor 
testing environments. In an analytical laboratory, reference samples are run in addition to 
the test samples, allowing the calibration of measured values to defined reference 
standards. However, even sophisticated analytical instruments (e.g., mass spectrometers) 
are prone to matrix effects, where their measurements change depending on the type of 
sample or sometimes even matrix variations across samples of the same type. These matrix 
effects can be greatly exaggerated by the simplified assay chemistries used in point-of-care 
diagnostics, making the creation of a calibration curve in the field infeasible. Use of pure 
chemical reference standards is thus not appropriate. Use of reference standards in the same 
matrix (e.g., blood) also presents a number of problems, from inter-individual variability 
in sample matrices that can impact assay readouts to lack of availability of appropriate 
reference material for each calibration value (e.g., availability of sufficient blood samples 
naturally depleted in a given biomarker for distribution to all test users). 
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 Our approach addresses these issues by using the patient sample itself as the sample 
matrix for the parallel calibration standards. However, this raises another issue: the patient 
sample itself contains the biomarker to be measured, so how can calibration samples have 
fixed levels of the analyte when a variable amount of the analyte is to be added to those 
samples? We solve this problem in a generalizable way by saturating the samples with the 
biomarker analyte, and then using varying levels of a key reaction component (i.e., the 
biomarker-responsive transcriptional regulator) to recapitulate assay output for different 
levels of analyte. This insight is what ultimately allows for calibration standards to be run 
in the exact same matrix as the sample, increasing accuracy and robustness regardless of 
whether the test environment is resource-poor or not. 
 A major benefit of the approach presented here is the ability to interpret test output 
without any equipment. While simple instruments have been developed to interpret and 
process CFE colorimetric output15,16, cell-free tests could be more broadly used if 
interpretation did not require any equipment, since equipment costs as low as even a few 
hundred dollars can still be an impediment to adoption for public health organizations 
across the world. The broad color spectrum that corresponds with different levels of LacZ 
cleavage of CPRG enables such equipment-free interpretation.  
 Previous CFE diagnostics used CPR/CPRG as a readout to enable visibly 
interpretable results for binary positive/negative discrimination of test results. For 
diagnoses requiring some degree of biomarker quantification, a two-color approach is not 
easily generalizable in an equipment-free fashion. We showed the nearly-binary readout 
(yellow to purple, with difficult-to-distinguish intermediate hues) is caused by serum 
albumin (which is consistent with previous work using albumin-coated paper). Serum 
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albumin affects the absorbance spectrum of CPR in a way that mutes the intermediate range 
of possible colors, precluding the use of these visibly distinguishable intermediate colors 
when testing human serum. We overcame this issue by adding a molecule to completed 
assays that displaces CPR from albumin, restoring the full spectrum of colors and enabling 
truly equipment-free interpretation of test results even in high serum concentrations. 
 While our approach to semi-quantitation in CFE assays has significant value in its 
generalizability, the specific zinc assay we developed has significant inherent value. Zinc 
deficiency causes over 100,000 annual childhood deaths, yet financial and logistical 
constraints associated with current zinc assays (which require an analytical laboratory) 
preclude diagnosis and treatment. The test described here is readily translatable to public 
health and clinical diagnostic applications.  
 Of foremost importance, our test detects relevant concentrations of serum zinc. 
Physiological serum zinc concentrations range from 2 μM to 20 μM24 and clinically 
relevant thresholds for deficiency fall between 8.5 and 11.5 μM21. The developed test (in 
25% serum) reliably distinguishes 4 μM increments between 0 and 20 μM serum zinc. 
(Figure 40). (Finer resolution is arguably possible based on our results to date, but 4 μM 
resolution is clear.) This enables distinction between sufficient, borderline, and low serum 
zinc levels. When run in a higher percentage of serum, CFE reactions respond to a 
concentration range of 2 to 22 μM zinc (Figure 30D), meaning that lyophilized assay 
reactions could be directly rehydrated with 100% serum and still provide reasonable 
quantification with perhaps even finer resolution. Here, we developed the proof-of-
principle regulator concentrations for calibration in a 25% serum matrix for experimental 
simplicity and throughput (as lyophilization can be a bottleneck), but the regulator 
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concentrations for a 100% serum matrix could be developed in an identical fashion using 
lyophilized samples. 
 In addition, the developed test meets the requirements for field-friendly testing18, 
in large part because it requires minimal equipment and processing steps. Since the clinical 
marker for zinc deficiency is serum or plasma zinc, a burden for any zinc test is the removal 
of red blood cells from patient samples. However, this can be easily accomplished using 
field-friendly blood separation methods that use no electricity109 and that could potentially 
further streamline the processing and testing pipeline119.  
 Beyond serum separation, the remainder of the required processing steps would be 
minimal. We have shown that our CFE sensor works even in 100% serum, meaning that 
minimal measurement or pipetting should be necessary. Even using 25% serum would 
require only a single 1:4 dilution for rehydration of lyophilized reactions, with no other 
processing. Finally, we note that all of these reactions are done at microliter scales, 
meaning that easily acquired finger-stick blood samples will provide sufficient sample 
(rather than necessitating venous blood draws that require a trained phlebotomist and have 
reduced patient acceptance). 
 Though we chose to measure zinc (based on its global public health relevance) for 
our proof-of-principle demonstration of equipment-free quantitation, the quantitation 
method used here can be easily applied to other CFE diagnostic sensors. Any sensor based 
on transcription factors that sense a biomarker analyte and propagate this signal based on 
transcription could be directly substituted into the current design by determining the 
correlation between transcription factor concentrations and target analyte concentrations. 
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Further, we showed that this approach can be easily generalized even to CFE diagnostics 
not mediated by transcription factors, including previously-described nucleic acid 
detection devices. Within about one week in the laboratory, we were able to calibrate a 
toehold switch sensor and demonstrate that it could reliably quantify input DNA.  
 In our test development and evaluation, we assumed that the human eye could 
differentiate between ten percent differences of the available color spectrum, and we set 
assessment thresholds accordingly. Though opinions may vary about just how different 
two colors must be in order to be distinguishable, the heuristic we use here is nonetheless 
useful as a guideline, and it can be refined as necessary to more specifically determine test 
resolution and performance under different assumptions. Alternatively, if previously-
developed, relatively low-cost instruments for absorbance readings15 are feasible for field 
deployment, our parallelized calibration approach can provide even greater resolution and 
higher confidence in measured values than the strictly visual approach assumed here. 
 The development of cell free expression systems for diagnostics was a watershed 
moment in synthetic biology that can now be brought to bear on sensing molecules beyond 
nucleic acids. By enabling semi-quantitative analysis of biomarker levels even in low-
resource environments, we have expanded the potential of CFE diagnostics by broadening 
the scope of conditions they can assess beyond nucleic acids and infectious diseases. The 
combination of simplicity and semi-quantitative resolution of our approach suggests that it 
may be useful not only in resource-poor environments, but even as a low-cost clinical 
screen to determine if more precise (and expensive) assays are necessary. The zinc assay 
reported here and assays developed via translations of the diagnostic platform described 
here could thus have a truly broad and global reach.  
 123 
 CONCLUSIONS AND FUTURE DIRECTIONS 
 I have presented the development of two different biosensing approaches that 
enable semiquantitative, equipment-free assessment of biomarkers in complex biological 
samples. I used these biosensors to assess zinc concentrations in human serum, moving 
closer to a field-deployable diagnostic for zinc deficiency. In this chapter, I will discuss the 
novelty and contribution of my thesis research, the remaining steps required to begin in-
field zinc assessment, and how the biosensing platforms I developed can be extended to 
create new classes of diagnostics and therapeutics.  
5.1 Novelty of thesis research 
 While biosensors have been developed for a wide variety of compounds, very few 
have been turned into deployable diagnostic tools, largely because of the challenges of in-
field test assessment, sensor response range, and the matrix effects inherent to clinical 
samples. In both my whole-cell and cell-free development work, I developed novel 
approaches to overcome these problems, and these should be readily translatable to the 
creation of new types of sensors.  
 In developing a whole-cell zinc sensor, I showed how synthetic biology tools can 
be used to harness metabolite production, rather than protein production, to facilitate the 
creation of responsive metabolic factories. While previous research has built complex 
bacterial systems, nearly all synthetic biology work uses simple reporter proteins in 
building complex circuits, and nearly all metabolic engineering work uses simple circuits 
to control metabolite production. Integrating advanced circuitry with production of 
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complex chemicals poses unique challenges, and the tools I developed to tightly control 
metabolite production upon differential signal recognition can help to build new types of 
complex, responsive systems. 
 In recent years, cell-free systems have garnered great attention for their use as low-
cost, field-deployable diagnostic tools, but they have been almost exclusively used for 
assessment of infectious diseases, and they have all required extensive upstream sample 
processing. A huge array of diseases and conditions require precise quantification — rather 
than just presence/absence assessment — of relevant biomarkers, and cell-free systems had 
been poorly equipped to do this. The quantification method I developed can expand the 
scope of cell-free diagnostics to entire new classes of diseases and conditions, and the 
matrix-specific quantification strategies I developed can minimize the sample processing 
required so that minimally-trained users can perform tests in minimally-equipped settings. 
These tests could help to expand healthcare to low-resource areas and even enable at-home 
health monitoring.  
5.2 Development of a field-deployable biosensor for zinc deficiency 
 I initially aimed to develop a fast-responding biosensor to serve as the basis of a 
diagnostic for zinc deficiency, and in both my whole-cell and cell-free sensor development 
efforts, I have met this goal. Both respond to physiologically relevant zinc concentrations, 
can be interpreted without equipment, and require short incubation times. While both 
systems could potentially serve as the basis of a point-of-care diagnostic, the form factor 
of the cell-free assay makes it much more amenable to in-field micronutrient assessment.  
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 The cell-free test I developed for serum zinc is imminently translatable: it requires 
just a finger prick of blood, can be lyophilized, and produces results within one hour. 
However, bridging the gap from lab success to in-field use requires a few additional steps. 
First, we need to calibrate the zinc diagnostic with real clinical serum samples. All serum 
samples analyzed to date have been collected from healthy donors, and we created 
artificially deficient serum samples by depleting zinc with Chelex-100, an ion-binding 
resin. Beyond removing zinc ions, the depletion process introduces slight, but still 
detectable, matrix effects that alter the output of CFE reactions. To make a test that 
accurately quantifies zinc in the matrix of untreated serum samples, we must calibrate the 
test with collected, unprocessed serum that has a range of zinc concentrations. I have 
spoken with a researcher at the Center for Disease Control (CDC) about obtaining aliquots 
of serum samples collected in previous nutrition assessments. Using these samples, we 
could create a calibration curve that we could use to quantify zinc in unprocessed serum 
samples. 
 Moving towards in-field testing would also require more extensive validation of 
our test manufacturing and storage processes. While we have demonstrated that lyophilized 
tests can be rehydrated in a serum sample and still accurately quantify zinc, we need to 
demonstrate that tests can be stored for extended periods of time, and in diverse 
temperature and pressures that reflect the conditions throughout the storage and shipment 
process. This assessment should be straightforward to complete, but poor performance of 
tests following long-term storage could require optimization of lyophilization and test 
packaging. 
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 To make the testing process more streamlined, the CFE reactions could be 
incorporated into a paper microfluidic device that can separate serum from red blood cells. 
Such a device would eliminate the need for a separate processing step and thus simplify 
the testing process: Upon addition of a finger prick of blood, the device would separate 
serum from red blood cells, and the serum would rehydrate lyophilized CFE reactions. 
Advances in paper manufacturing could enable the entire testing process to occur in a self-
contained device20,120, insulated from the environment to control for evaporation. Through 
collaborations with groups at Georgia Tech that specialize in paper manufacturing, we are 
working to integrate our cell-free zinc assay into such a device.  
 Though a streamlined testing device would make the test even more field-friendly, 
integration of serum separation and biomarker assessment is not a critical requirement for 
field deployability. An inexpensive, portable, paper-based centrifuge109 could alternatively 
be used to separate serum from blood. This serum could be used to rehydrate reactions 
lyophilized in tubes, and by simply closing the tubes, the reactions would be protected from 
evaporation and environmental contaminants.  
 Once tests are calibrated with real clinical samples and the storage process is 
optimized and validated, we can begin sending tests for pilot testing. Early in graduate 
school, I participated in NSF’s I-Corps program to explore the commercialization potential 
of point-of-care micronutrient assays, specifically to learn whether there is a need for low-
cost micronutrient tests and what requirements such tests must meet. I spoke with people 
at all levels of the nutritional surveillance pipeline: the leaders of organizations like 
UNICEF and the World Health Organization, program managers leading micronutrient 
assessment and intervention programs in Ethiopia, and academic researchers who evaluate 
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the effectiveness of different nutritional intervention strategies. Beyond hearing an 
overwhelming consensus that there is a great need for point-of-care assessment tools, I also 
made contacts with many people who expressed interest in testing a final, functional 
device. We could directly work with these people to begin pilot testing; or alternatively, 
we could work with PATH, an organization associated with the Bill and Melinda Gates 
Foundation that helps to facilitate collaborations between engineers, aid agencies, and 
companies so that technologies with global health applications can be fully validated, 
assessed, and produced at scale. PATH has previously expressed interest in incorporating 
our final zinc assay into their micronutrient assessment platform, which would be a 
potentially easier and more straightforward way to get our test into the hands of the people 
who need it. 
5.3 Expansion of cell-free quantification platform to new biomarkers 
 Beyond creating a nearly field-deployable assay for zinc deficiency, I have created 
a generalizable quantification platform that can be expanded to assess a diversity of 
clinically relevant biomarkers. We have already demonstrated that our matrix-specific 
calibration approach can quantify different types of biomarkers (ions and nucleic acids) 
with different sensing methods (transcription factors and riboregulators). The platform can 
be easily used to quantify other types of biomarkers that have sensor and transducer 
elements that function in CFE reactions. 
 The primary challenge for using our system to quantify other clinically relevant 
biomarkers are limitations in naturally occurring sensors that specifically bind the target 
biomarker at relevant concentrations. Biomarkers that interact with bacterial transcription 
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factors should be immediately detectable in our cell-free platform, but the range of 
detection may fall outside the relevant concentration range. For example, I have used a 
cobalamin-responsive transcription factor to quantify B12 (another micronutrient of global 
health importance) in cell free reactions, but the sensor responds to concentrations far 
higher than those required for clinical B12 assessment. Protein engineering strategies could 
be used to increase sensitivity, but to do so efficiently would require extensive effort and 
high-throughput screening. While nature has evolved sensors for diverse types of 
compounds, finding sensors that detect clinically relevant biomarker concentrations will 
likely be a continued challenge. 
 The use of modular sensors, such as aptamers or antibody fragments, is a promising 
alternative to bioprospecting. Aptamers and antibody fragments can be readily evolved to 
specifically bind a target molecule with a user-defined affinity121,122, which would enable 
the production of sensor systems for essentially arbitrary small molecules and proteins. To 
make diagnostics that use these interchangeable and evolvable sensor components, the 
primary challenge is making a reliable and modular signal transduction system so that 
target binding leads to a detectable change in transcription or translation. Small molecule-
binding aptamers can be incorporated into riboswitches or ribozymes123-125, which are RNA 
structures that differentially regulate either translation or transcription upon target binding. 
Though incorporation of new aptamers into these systems is notoriously difficult, 
thermodynamic prediction models have helped facilitate rational aptamer incorporation 
into RNA regulators78. Antibody fragments can be fused to transcription factors to enable 
differential gene expression upon target binding126,127, but this regulation scheme has not 
yet been explored in the context of a cell-free reaction. Though creating aptamer and 
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antibody-based tests will require significant development, the resulting CFE assays could 
dramatically expand the scope of health surveillance programs, clinical diagnoses, and 
even at-home health assessment.  
 The company Theranos aimed to transform healthcare by making easy-to-use, 
small volume tests that could replace standard lab assay. Though the company failed to 
deliver functional products, the excitement and investment that Theranos generated 
illustrates the great public interest in changing the diagnostic paradigm with point-of-care 
tests128. Cell-free diagnostics have the potential to serve as the basis for this sort of 
diagnostic revolution. While these tests could be interpreted visually, they could also be 
incorporated into a minimal-equipment testing framework for automated, more precise 
quantification. A user could add a cartridge of lyophilized test and standard reactions for 
any desired biomarker to a low-cost absorbance reader, and use serum from just a finger 
prick of blood to rehydrate and activate the tests. The reader would then report a more 
precise, matrix-normalized biomarker concentration. These tests — whether interpreted 
visually or with equipment — would enable at-home health monitoring or could be used 
be used as rapid initial screens in clinics before ordering more expensive laboratory panels. 
5.4 Microbial factories for targeted chemical production 
 Since the cell-free zinc sensor I developed is much more field-friendly than the 
developed whole-cell sensor, I find it unlikely that the whole cell zinc sensor will ever turn 
into a clinical assay. However, the methods that I developed to control microbial metabolite 
production (in the context of a zinc biosensor) are directly translatable to other systems that 
require precise chemical production upon sensing a specific target. Our approaches can be 
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directly applied to the development of pigment-based biosensors for new compounds or to 
the creation of “smart” bacterial therapies that produce a chemical upon sensing a target 
compound. 
 Whole cell biosensors could overcome some of the current limitations of cell-free 
diagnostics, specifically the lack of available sensors that are sensitive enough to detect 
clinically relevant concentrations of target biomarkers. Bacterial cells have exceptional 
environmental scavenging systems, which allow them to sense and respond to very small 
changes in their extracellular environments. Cell-free sensors cannot harness these 
scavenging systems and can only use the intracellular sensor proteins, which may respond 
to analyte concentrations orders of magnitude higher than extracellular concentrations. 
Thus, a whole-cell sensor would be more useful for sensitive detection of compounds that 
are actively transported into cells. The circuits I constructed for a pigment-based zinc test 
could be directly applied to detection of a new compound by simply replacing the zinc-
responsive promoter PzntA with a promoter that responds to a different biomarker. The same 
tuning approaches we used — modulation of regulator levels — can be used to tune the 
response ranges of the new sensor, enabling fast creation of tunable, pigment-based sensors 
for sensitive detection of different types of compounds. In ongoing, currently unpublished 
work, I am porting B12-responsive elements into these circuits to create a colorimetric 
whole-cell B12 sensor.  
 The approaches we used to make a pigment-based sensor could also be used to 
make tunable sensors that produce different types of metabolites. These cells could serve 
as “theranostics” that produce a therapeutic payload upon target recognition. Responsive 
bacterial therapies have already been developed for treatment of cancer10,11, metabolic 
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disorders12,13, and inflammation14, but nearly all produce individual proteins upon target 
recognition. Cells that produce complex chemicals (made via metabolic pathways) upon 
target recognition could dramatically expand the types of therapeutics that could be 
delivered. For example, bacteria could be engineered to produce a chemotherapeutic agent 
only upon recognition of a specific cancer biomarker. Bacterial cells have already been 
engineered to produce precursors for the chemotherapuetic Taxol82, and they can also 
recognize metabolic states specific to the cancer microenvironment (such as elevated 
aspartate levels129). A potential bacterial therapeutic could combine these two capabilities 
so that cells produce Taxol only upon recognition of some threshold level of aspartate and 
— importantly — be inactive upon sensing baseline aspartate present in healthy organs. 
While metabolic engineering advances are certainly required to make this possible, the 
strategies this thesis developed for tunable, precise metabolite production could help enable 
the creation of this sort of therapy. Similar approaches could be applied to the creation of 
bacterial theranostics that modulate the gut microbiome. As we learn more about the 
microbiome’s role in disease, there will likely be an increased demand for responsive 
microbial therapies to regulate the microbiome. Whole cells, rather than cell-free systems, 
are the ideal platform for drug delivery to the microbiome, because cells are self-contained, 
are optimized for survival in the host, and can colonize the host to serve as a continued 
delivery source130. 
 While the strategies I developed to control metabolism could be broadly applied to 
creation of these theranostics, the specific approaches would vary based on the application. 
In creation of our whole-cell sensor, we used the repressor LacI as the master controller of 
the pigment production system, which fully repressed metabolic output during cell growth 
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to enable faster response upon induction and higher cell viability. For our application, 
adding LacI’s chemical inducer (IPTG) at the time of testing was a viable strategy. 
However, for drug delivery within the body, this type of control would be difficult to 
implement. Alternative strategies could use transcription factors that respond to hypoxia (a 
characteristic of tumors)12 or to xylan (an ingestible inducer)131 to control when the sensing 
system is active. Beyond enabling faster responses, these control methods would serve as 
additional checks on drug production to prevent leaky, unwanted drug production in other 
parts of the body. 
5.5 Closing remarks 
 In this thesis, I have described my efforts to engineer bacterial-based biosensors for 
use as diagnostic tools in low-resource settings. I developed ways to decouple bacterial 
growth from production of a target metabolite, which enables cell sensors to produce 
visible pigment within just a few hours of sample addition. I then incorporated zinc-
responsive elements into this fast-responding sensor scaffold, and tuned the sensor’s 
response range to enable fast assessment of physiologically relevant zinc concentrations in 
serum samples. By simply replacing either the zinc-responsive elements or pigment 
pathways, a user could create and tune sensors cells that selectively make metabolic 
compounds upon detection of a specific signal, enabling the creation of other types of 
diagnostics and responsive chemical production systems.  
 By porting the zinc-responding sensing machinery into a cell-free platform, I 
created a test for zinc that meets all of the WHO’s ASSURED criteria and all of the 
requirements for in-field micronutrient assessment. Following minimal additional 
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calibration and validation, the test will be ready to send to researchers or aid agencies for 
initial pilot testing. This test can meet the need for an easy-to use, equipment-free assay 
that can help provide the information necessary for efficient and effective treatment of zinc 
deficiency. 
 In creating a cell-free zinc test, I developed a matrix-specific standardization 
approach that can drastically broaden the reach of cell-free diagnostics. Cell-free 
diagnostics, which had previously been restricted to simply presence/absence detection, 
can now assess different types of biomarkers in an equipment-free semiquantitative 
fashion, enabling the creation of low-cost, point-of-care diagnostics for a wide variety of 
diseases and conditions. While I showed that our test effectively quantifies zinc and nucleic 
acids, expansion to other markers will require development of sensors that bind to the target 
biomarker at the desired concentration. Developing cell-free sensors has become a major 
focus of our group, and ongoing and future research projects aim to develop a versatile 
sensing approach to enable detection of diverse types of biomarkers.  
 Through conversations with policy makers and aid workers, I learned of the huge 
impact that point-of-care tests could have on implementation and assessment of large-scale 
public health programs. This thesis has presented the development of a diagnostic tool to 
meet the need for in-field zinc assessment, and has laid the groundwork for the creation of 
diverse diagnostic assays that have the potential to broaden the scope of public health 
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